U.S. patent application number 13/672628 was filed with the patent office on 2013-08-01 for films and particles.
This patent application is currently assigned to THE TRUSTEES OF THE BOSTON UNIVERSITY. The applicant listed for this patent is The Brigham and Women's Hospital, The Trustees of the Boston University. Invention is credited to Solomon Azouz, Yolonda L. Colson, Mark W. Grinstaff, Aaron Griset, Jesse Wolinsky.
Application Number | 20130195954 13/672628 |
Document ID | / |
Family ID | 39225211 |
Filed Date | 2013-08-01 |
United States Patent
Application |
20130195954 |
Kind Code |
A1 |
Colson; Yolonda L. ; et
al. |
August 1, 2013 |
FILMS AND PARTICLES
Abstract
Described herein are compounds and processes that can be used to
prepare polymer-based films, particles, gels and related
compositions, and processes for delivery of agents, and other
uses.
Inventors: |
Colson; Yolonda L.; (Dover,
MA) ; Azouz; Solomon; (Dallas, TX) ;
Grinstaff; Mark W.; (Brookline, MA) ; Wolinsky;
Jesse; (Brookline, MA) ; Griset; Aaron;
(Medford, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The Brigham and Women's Hospital;
The Trustees of the Boston University; |
Boston
Boston |
MA
MA |
US
US |
|
|
Assignee: |
THE TRUSTEES OF THE BOSTON
UNIVERSITY
Boston
MA
THE BRIGHAM AND WOMEN'S HOSPITAL
Boston
MA
|
Family ID: |
39225211 |
Appl. No.: |
13/672628 |
Filed: |
November 8, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12690607 |
Jan 20, 2010 |
8334324 |
|
|
13672628 |
|
|
|
|
11756587 |
May 31, 2007 |
7671095 |
|
|
12690607 |
|
|
|
|
60809344 |
May 31, 2006 |
|
|
|
60844122 |
Sep 13, 2006 |
|
|
|
Current U.S.
Class: |
424/443 ;
428/402; 514/265.1; 514/449; 514/772.4; 526/266; 526/268;
549/370 |
Current CPC
Class: |
A61P 11/06 20180101;
A61K 31/519 20130101; A61P 21/06 20180101; A61P 35/00 20180101;
A61K 38/50 20130101; A61K 47/32 20130101; A61K 31/337 20130101;
A61P 29/00 20180101; A61K 38/14 20130101; A61P 31/00 20180101; A61P
23/00 20180101; A61P 31/12 20180101; C07D 319/06 20130101; A61P
17/02 20180101; Y10T 428/2982 20150115; A61P 35/02 20180101; C08F
124/00 20130101 |
Class at
Publication: |
424/443 ;
549/370; 514/772.4; 514/449; 514/265.1; 526/266; 526/268;
428/402 |
International
Class: |
A61K 47/32 20060101
A61K047/32; C08F 124/00 20060101 C08F124/00; A61K 31/519 20060101
A61K031/519; C07D 319/06 20060101 C07D319/06; A61K 31/337 20060101
A61K031/337 |
Goverment Interests
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with Government support under U.S.
Army Cooperative agreement No. DAMD-17-02-2-0006. The Government
has certain rights in the invention.
Claims
1. An oligomer or polymer having a repeat unit represented by
Formula XX: ##STR00083## wherein: Q is selected from O, S, Se, and
NH; G is selected from among the following structures: ##STR00084##
##STR00085## R.sub.2 is selected from hydrogen, a straight or
branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl,
arylsilyl, alkylaryl, arylalkyl, and fluorocarbon chain of 1-50
carbons, wherein each alkyl, cycloalkyl, aryl, olefin, silyl,
alkylsilyl, arylsilyl, alkylaryl, arylalkyl, or fluorocarbon chain
is optionally substituted internally or terminally by one or more
hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide,
amino, mono- or di-substituted amino, thiol, thioester, sulfate,
phosphate, phosphonate, or halogen substituents; R.sub.3 is
selected from hydrogen, methoxy, ethoxy, amino, a straight or
branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl,
arylsilyl, alkylaryl, and arylalkyl chain of 1-10 carbons; R.sub.4,
R.sub.5, and R.sub.6 are each independently selected from a
straight or branched alkyl, cycloalkyl, aryl, olefin, silyl,
alkylsilyl, arylsilyl, alkylaryl, and arylalkyl chain of 1-10
carbons; and R.sub.7 and R.sub.8 are each independently selected
from hydrogen, a straight or branched alkyl, cycloalkyl, aryl,
olefin, alkylaryl, and arylalkyl chain of 1-50 carbons, wherein
each alkyl, cycloalkyl, aryl, olefin, alkylaryl, or arylalkyl chain
is optionally substituted internally or terminally by one or more
hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide,
amino, mono- or di-substituted amino, thiol, thioester, sulfate,
phosphate, phosphonate, or halogen substituents.
2. The oligomer or polymer of claim 1, wherein the oligomer or
polymer is represented by Formula XX': ##STR00086## wherein: n is
an integer from 2-750, and wherein each oligomeric or polymeric
chain has a terminal group, the terminal group being selected from
among amines, thiols, amides, phosphates, sulphates, hydroxides,
alkenes, and alkynes.
3. The oligomer or polymer of claim 1, wherein R.sub.2 is hydrogen
or methyl.
4. The oligomer or polymer of claim 1, wherein Q is oxygen.
5. A composition comprising the oligomer or polymer of claim 1.
6. A polymeric film or particle comprising an oligomer or polymer
of claim 1.
7. A polymeric particle of claim 6, comprising a microparticle or
nanoparticle.
8. A polymeric particle of claim 7, wherein the particle has a
diameter between about 2 nm and 1 micron.
9. The polymeric particle of claim 7 comprising a first volume at a
first pH, and a second volume at a second pH, different from the
from the first pH.
10. The polymeric particle of claim 9, wherein the second volume is
1.times. or more greater than the first volume when the second pH
is lower than the first pH.
11. The polymeric particle of claim 9, wherein the second volume is
4.times. or more greater than the first volume when the second pH
is lower than the first pH.
12. The polymeric particle of claim 9, wherein the second volume is
8.times. or more greater than the first volume when the second pH
is lower than the first pH.
13. The polymeric particle of claim 9, wherein the second volume is
greater than the first volume and the change in volume is
sufficient that the particle when within a cell during the volume
change ruptures the cell or a cellular compartment.
14. The polymeric particle of claim 9, wherein the second volume is
greater than the first volume and the change in volume is
sufficient to cause the particle to become lodged, embedded, or
immobilized in an anatomic location, such as a lymph node, airway,
cavity, capillary, or other tissue.
15. The polymeric film or particle of claim 6, further comprising
an agent.
16. The polymeric film or particle of claim 15, wherein the agent
is a biologically active agent comprising one or more of an
anti-cancer agent, an anti-biotic, an anti-neoplastic agent, an
analgesic, an angiogenic, or an agent that promotes wound
healing.
17. The polymeric film or particle of claim 15, wherein the
biologically active agent comprises one or more of asparaginase;
bleomycin; busulfan; capecitabine; carboplatin; carmustine
chlorambucil; cisplatin; cyclophosphamide; cytarabine; dacarbazine;
dactinomycin; daunorubicin; dexrazoxane; docetaxel; doxorubicin;
etoposide; floxuridine; fludarabine; fluorouracil; gemcitabine;
hydroxyurea; idarubicin; ifosfamide; irinotecan; lomustine;
mechlorethamine; melphalan; mercaptopurine; methotrexate;
mitomycin; mitotane; mitoxantrone; paclitaxel; pemetrexed;
pentostatin; plicamycin; procarbazine; rituximab; streptozocin;
teniposide; thioguanine; thiotepa; vinblastine; vincristine; and
vinorelbine.
18. (canceled)
19. The film of claim 6, wherein the film is a single layered
film.
20. The film of claim 15, further comprising two or more layers to
form a multi-layered film.
21. The film of claim 15, comprising a first layer comprising a
first polymer of Formula XX, and a second layer comprising a second
polymer different from Formula XX.
22. The film of claim 21, wherein the second polymer comprises one
or more of poly(lactic acid), poly(glycolic acid),
poly(lactic-co-glycolic acid), polycaprolactone, poly(trimethylene
carbonate), polyester, polycarbonate, and polyamide.
23-41. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of Ser. No. 12/690,607,
filed Jan. 20, 2010, which is a divisional of Ser. No. 11/756,587,
filed May 31, 2007, which in turn claims the benefit of priority of
U.S. Prov. Appl. Ser. No. 60/809,344, filed on May 31, 2006, and
U.S. Prov. Appl. Ser. No. 60/844,122, filed on Sep. 13, 2006, each
of which are incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[0003] Provided herein are compounds and processes to prepare
polymer based films, particles, gels, and related compositions, and
processes for delivery of agents.
BACKGROUND OF THE INVENTION
[0004] Medicine traditionally utilizes pharmacologic agents or
surgical interventions for the treatment of disease. Specific
targeting or localization of pharmacologic or biological agents to
desired organs and tissues is a complex challenge. For example,
cancer is a leading cause of death for both men and women in the
United States (Jemal et al., CA Cancer J. Clin., 56:106-130, 2006).
Current methods of cancer treatment include chemotherapy, radiation
treatment, and surgical resection. As evidenced by high rates of
cancer recurrence and low survival, treatments of conditions such
as cancer often remain relatively ineffective.
[0005] Other diseases and conditions which utilize drug delivery
technologies include immunological applications, pain control,
wound healing, infectious disease, transplants, and the development
of vaccines. Potential drug candidates often present solubility,
toxicity, and pharmacokinetic considerations. Thus, there is a
widespread need for targeted and sustained delivery of therapeutic
agents.
[0006] Certain polyesters, polycarbonates, and polyamides are
biodegradable polymers with low toxicity and degradation
properties. Such polymers include poly(.epsilon.-caprolactone),
poly(p-dioxanone), poly(trimethylene carbonate), poly(amino acids),
and most notably poly(glycolic acid) and polylactic acid) (see,
e.g., Agrawal et al., Biomaterials, 13:176-182, 1992; Attawia et
al., J. Biomed. Mater. Res., 29:1233-140, 1995; Heller et al., Adv.
Drug Deliv. Rev., 54:1015-1039, 2002; Miller and Williams,
Biomaterials, 8:129-137, 1987; and Athanasiou et al., Arthroscopy,
14:726-737, 1998). These polymers are used in a variety of
applications including the delivery of therapeutic agents. However,
physical properties of the aforementioned polymers are often
limited by monomer selection, polymerization techniques, and
post-polymerization modifications. Properties of interest include
thermal transition temperatures, bulk strength, flexibility,
elasticity, degradation, crystallinity, and hydrophobicity. When
polymers are utilized for in vivo applications, the physical
properties of the material affect host response. Hence, a need
exists for polymers and delivery systems with desired
characteristics that are effective for treatment of diseases and
conditions.
SUMMARY OF THE INVENTION
[0007] The invention is based, at least in part, on the discovery
that certain polymer films and particles can be utilized
therapeutically and/or cosmetically. For example, many of the films
and particles described herein can be used for the controlled,
localized, and sustained delivery of various agents for treatment
of diseases and conditions. Provided herein are compounds and
processes to prepare polymer based films, particles, gels, and
related compositions, and processes for delivery of agents.
Provided herein are polymeric films and particles that deliver one
or more agents, such as one or more therapeutic agents, to a local
site, where the release of the one or more agents from the film or
particle is initiated by a pH change. Also provided are
biodegradable polymers.
[0008] In one aspect, the invention features oligomers or polymers
having a repeat unit represented by Formula XX:
##STR00001##
In such oligomers or polymers, Q is selected from among O, S, Se,
or NH; G is selected from among the following structures:
##STR00002## ##STR00003##
R.sub.2 is selected from among hydrogen, a straight or branched
alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl,
alkylaryl, arylalkyl, or fluorocarbon chain of 1-50 carbons,
wherein each alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl,
arylsilyl, alkylaryl, arylalkyl, or fluorocarbon chain is
optionally substituted internally or terminally by one or more
hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide,
amino, mono- or di-substituted amino, thiol, thioester, sulfate,
phosphate, phosphonate, or halogen substituents; R.sub.3 is
selected from among hydrogen, methoxy, ethoxy, amino, a straight or
branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl,
arylsilyl, alkylaryl, or arylalkyl chain of 1-10 carbons; R.sub.4,
R.sub.5, and R.sub.6 are each independently selected from among a
straight or branched alkyl, cycloalkyl, aryl, olefin, silyl,
alkylsilyl, arylsilyl, alkylaryl, or arylalkyl chain of 1-10
carbons; and R.sub.7 and R.sub.8 are each independently selected
from among hydrogen, a straight or branched alkyl, cycloalkyl,
aryl, olefin, alkylaryl, or arylalkyl chain of 1-50 carbons,
wherein each alkyl, cycloalkyl, aryl, olefin, alkylaryl, or
arylalkyl chain is optionally substituted internally or terminally
by one or more hydroxyl, hydroxyether, carboxyl, carboxyester,
carboxyamide, amino, mono- or di-substituted amino, thiol,
thioester, sulfate, phosphate, phosphonate, or halogen
substituents.
[0009] In some embodiments, the oligomers or polymers are
represented by Formula XX':
##STR00004##
In such embodiments, n is an integer from 2-750, and each
oligomeric or polymeric chain has a terminal group, the terminal
group being selected from among amines, thiols, amides, phosphates,
sulphates, hydroxides, alkenes, and alkynes.
[0010] In another aspect, the invention features oligomers or
polymers, or portions thereof, that are represented by Formula XXI,
XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI,
XXXII, XXXIII, XXXIV, XXXV, XXXVI or XXXVII:
##STR00005## ##STR00006## ##STR00007##
In such oligomers or polymers, or portions thereof, Q' is
independently selected from among O, S, Se, or NH; G', G.sub.1',
and G.sub.2' are each independently selected from among the
following structures:
##STR00008##
or R.sub.1'.
[0011] G.sub.1' and G.sub.2' are not the same; R.sub.1' is selected
from among a straight or branched alkyl, cycloalkyl, aryl, olefin,
silyl, alkylsilyl, arylsilyl, alkylaryl, arylalkyl, or fluorocarbon
chain of 3-50 carbons, wherein each alkyl, cycloalkyl, aryl,
olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, arylalkyl or
fluorocarbon chain is optionally substituted internally or
terminally by one or more hydroxyl, hydroxyether, carboxyl,
carboxyester, carboxyamide, amino, mono- or di-substituted amino,
thiol, thioester, sulfate, phosphate, phosphonate, or halogen
substituents; or R.sub.1' is selected from among poly(ethylene
glycol), poly(ethylene oxide), poly(hydroxyacid)), a carbohydrate,
a protein, a polypeptide, an amino acid, a nucleic acid, a
nucleotide, a polynucleotide, any DNA or RNA segment, a lipid, a
polysaccharide, an antibody, a pharmaceutical agent, or any epitope
for a biological receptor; or R.sub.1' is selected from among a
photocrosslinkable or ionically crosslinkable group; R.sub.2' is
selected from among hydrogen, a straight or branched alkyl,
cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl,
arylalkyl, or fluorocarbon chain of 1-50 carbons. Each alkyl,
cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl,
arylalkyl, or fluorocarbon chain is optionally substituted
internally or terminally by one or more hydroxyl, hydroxyether,
carboxyl, carboxyester, carboxyamide, amino, mono- or
di-substituted amino, thiol, thioester, sulfate, phosphate,
phosphonate, or halogen substituents; x and y are each
independently selected from an integer of 2-750; a is selected from
an integer of 1-25; b is selected from an integer of 1-14; c is
selected from an integer of 1-14; and each polymeric terminal group
is selected from among amines, thiols, amides, phosphates,
sulphates, hydroxides, metals, alkanes, alkenes and alkynes.
[0012] In another aspect, the invention features oligomers or
polymers, or portions thereof, represented by Formula XXXVIII:
##STR00009##
In such oligomers or polymers, or portions thereof, Q' is
independently selected from among O, S, Se, or NH; G' is selected
from among
##STR00010##
or R.sub.1'; R.sub.1' is selected from among a straight or branched
alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl,
alkylaryl, arylalkyl, or fluorocarbon chain of 3-50 carbons,
wherein each alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl,
arylsilyl, alkylaryl, arylalkyl, or fluorocarbon chain is
optionally substituted internally or terminally by one or more
hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide,
amino, mono- or di-substituted amino, thiol, thioester, sulfate,
phosphate, phosphonate, or halogen substituents; or R.sub.1' is
selected from among poly(ethylene glycol), poly(ethylene oxide),
poly(hydroxyacid)), a carbohydrate, a protein, a polypeptide, an
amino acid, a nucleic acid, a nucleotide, a polynucleotide, any DNA
or RNA segment, a lipid, a polysaccharide, an antibody, a
pharmaceutical agent, or any epitope for a biological receptor; or
R.sub.1' is selected from among a photocrosslinkable or ionically
crosslinkable group; x and y are each independently selected from
an integer of 2-750; e is selected from an integer of 1-8; and each
polymeric terminal group is selected from among amines, thiols,
amides, phosphates, sulphates, hydroxides, metals, alkanes, alkenes
and alkynes.
[0013] In another aspect, the invention features oligomers or
polymers having a repeat unit represented by Formula XX:
##STR00011##
In such oligomers or polymers G includes a first group that is
convertible to a second group different from the first group at a
pH at or below about 6.0, such as below about 5.5, 5.0 or 4.5;
R.sub.2 is selected from among hydrogen, a straight or branched
alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl,
alkylaryl, arylalkyl, or fluorocarbon chain of 1-50 carbons. Each
alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl,
alkylaryl, arylalkyl or fluorocarbon chain is optionally
substituted internally or terminally by one or more hydroxyl,
hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or
di-substituted amino, thiol, thioester, sulfate, phosphate,
phosphonate, or halogen substituents; and Q is selected from among
O, S, Se, or NH.
[0014] In another aspect, the invention features particles having a
first volume and including an oligomer or polymer having a repeat
unit represented by Formula XX:
##STR00012##
In such particles, G includes a first group that is convertible to
a second group different from the first group at a pH at or below
about 6.0, such as below about 5.5, 5.0, or 4.5; R.sub.2 is
selected from among hydrogen, a straight or branched alkyl,
cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl,
arylalkyl, or fluorocarbon chain of 1-50 carbons. Each alkyl,
cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl,
arylalkyl, or fluorocarbon chain is optionally substituted
internally or terminally by one or more hydroxyl, hydroxyether,
carboxyl, carboxyester, carboxyamide, amino, mono- or
di-substituted amino, thiol, thioester, sulfate, phosphate,
phosphonate, or halogen substituents; and Q is selected from among
O, S, Se, or NH. When the particle is placed in an environment
having a pH at or below about 6.0, the particle increases in volume
from the first volume to a second volume that is more than two
times the first volume after equilibrium is established.
[0015] Polymeric films or particles can include any oligomer or
polymer described herein. In some instances, the polymeric
particles include a first volume at a first pH, and a second volume
at a second pH, different from the from the first pH. For example,
the second volume is 1.times. or more greater than the first volume
when the second pH is lower than the first pH, such as 4.times. or
more greater than the first volume when the second pH is lower than
the first pH, or 8.times. or more greater than the first volume
when the second pH is lower than the first pH.
[0016] Any film or particle can include a therapeutic agent. For
example, the agent can be a biologically active agent comprising
one or more of an anti-cancer agent, an anti-biotic, an
anti-neoplastic agent, an analgesic, an angiogenic, or an agent
that promotes wound healing.
[0017] For example, the particles can be used for applying to one
or more of the following: (i) a surgical resection margin, (ii)
within a treated or untreated tumor or cavity, (iii) a target site
of disease away from a surgical margin, and (iv) a lymph node.
[0018] The particles or films can have one or more layers.
[0019] The particles can have a diameter or less than 500
nanometers, such as less than 250 nanometers or less than 100
nanometers. For example, the particles can have a diameter of
between about 1 nm and 2 microns.
[0020] Any of the particles described herein can be applied at a
first site, such as a surgical margin, and then are carried by the
body to a second site downstream of the first site, such as a lymph
node. In such uses, it is desirable that the particles have a
diameter of less than about 250 nanometers, such as less than 100
nanometers, or even less than 50 nanometers.
[0021] In another aspect, the invention features applying any film
or particle described herein to a site using sutures, staples,
and/or adhesives.
[0022] In another aspect, the invention features applying any film
or particle described herein to treat pain, or to alter healing,
e.g., to avoid scar formation.
[0023] Unless specific definitions are provided, e.g., as indicated
below, the nomenclature used in connection with, and the laboratory
procedures and techniques of, analytical chemistry, biochemistry,
synthetic organic chemistry, and medicinal and pharmaceutical
chemistry described herein are those known in the art. In the event
that there is a plurality of definitions for terms herein, those in
this section prevail.
[0024] As used herein, the abbreviations for any protective groups,
amino acids, and other compounds are, unless indicated otherwise,
in accord with their common usage, recognized abbreviations, or the
IUPAC-IUB Commission on Biochemical Nomenclature, Biochem.,
11:942-944 (1972).
[0025] As used herein, use of the singular includes the plural
unless specifically stated otherwise. As used herein, "or" means
"and/or" unless stated otherwise. Furthermore, use of the term
"including" as well as other forms, such as "includes," and
"included," is not limiting.
[0026] As used herein, the terms "treating" or "treatment"
encompass either or both responsive and prophylaxis measures, e.g.,
designed to inhibit, slow or delay the onset of a symptom of a
disease or disorder, achieve a full or partial reduction of a
symptom or disease state, and/or to alleviate, ameliorate, lessen,
or cure a disease or disorder and/or its symptoms.
[0027] As used herein, amelioration of the symptoms of a particular
disorder by administration of a particular compound or
pharmaceutical composition refers to any lessening of severity,
delay in onset, slowing of progression, or shortening of duration,
whether permanent or temporary, lasting or transient that can be
attributed to or associated with administration of the compound or
composition.
[0028] As used herein, the term "subject" is a human or an animal,
typically a mammal, such as a cow, horse, dog, cat, pig, sheep,
monkey, or other laboratory or domesticated animal. As used herein,
the term "patient" includes human and animal subjects.
[0029] As used herein, the term "carrier" refers to a compound that
facilitates the incorporation of another compound into cells or
tissues. For example, dimethyl sulfoxide (DMSO) is a commonly used
carrier for improving incorporation of certain organic compounds
into cells or tissues.
[0030] As used herein, the term "pharmaceutical composition" refers
to a chemical compound or composition capable of inducing a desired
therapeutic effect in a subject. In certain embodiments, a
pharmaceutical composition contains an active agent, which is the
agent that induces the desired therapeutic effect. The
pharmaceutical composition can contain a prodrug of the compounds
provided herein. In certain embodiments, a pharmaceutical
composition contains inactive ingredients, such as, for example,
carriers and excipients.
[0031] As used herein, the term "therapeutically effective amount"
refers to an amount of a pharmaceutical composition sufficient to
achieve a desired therapeutic effect.
[0032] As used herein, the term "pharmaceutically acceptable"
refers to a formulation of a compound that does not significantly
abrogate the biological activity, a pharmacological activity and/or
other properties of the compound when the formulated compound is
administered to a subject. In certain embodiments, a
pharmaceutically acceptable formulation does not cause significant
irritation to a subject.
[0033] As used herein, pharmaceutically acceptable derivatives of a
compound include, but are not limited to, salts, esters, enol
ethers, enol esters, acetals, ketals, orthoesters, hemiacetals,
hemiketals, acids, bases, solvates, hydrates, PEGylation, or
prodrugs thereof. Such derivatives can be readily prepared by those
of skill in this art using known methods for such derivatization.
The compounds produced can be administered to animals or humans
without substantial toxic effects and either are pharmaceutically
active or are prodrugs. Pharmaceutically acceptable salts include,
but are not limited to, amine salts, such as but not limited to
chloroprocaine, choline, N,N'-dibenzyl-ethylenediamine, ammonia,
diethanolamine and other hydroxyalkylamines, ethylenediamine,
N-methylglucamine, procaine, N-benzyl-phenethylamine,
1-para-chloro-benzyl-2-pyrrolidin-1'-ylmethyl-benzimidazole,
diethylamine and other alkylamines, piperazine and
tris(hydroxymethyl)-aminomethane; alkali metal salts, such as but
not limited to lithium, potassium and sodium; alkali earth metal
salts, such as but not limited to barium, calcium and magnesium;
transition metal salts, such as but not limited to zinc; and other
metal salts, such as but not limited to sodium hydrogen phosphate
and disodium phosphate; and also including, but not limited to,
salts of mineral acids, such as but not limited to hydrochlorides
and sulfates; and salts of organic acids, such as but not limited
to acetates, lactates, malates, tartrates, citrates, ascorbates,
succinates, butyrates, valerates and fumarates. Pharmaceutically
acceptable esters include, but are not limited to, alkyl, alkenyl,
alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl and
heterocyclyl esters of acidic groups, including, but not limited
to, carboxylic acids, phosphoric acids, phosphinic acids, sulfonic
acids, sulfinic acids and boronic acids. Pharmaceutically
acceptable enol ethers include, but are not limited to, derivatives
of formula C.dbd.C(OR) where R is hydrogen, alkyl, alkenyl,
alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, or
heterocyclyl. Pharmaceutically acceptable enol esters include, but
are not limited to, derivatives of formula C.dbd.C(OC(O)R) where R
is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl,
heteroaralkyl, cycloalkyl, or heterocyclyl. Pharmaceutically
acceptable solvates and hydrates are complexes of a compound with
one or more solvent or water molecules, or 1 to about 100, or 1 to
about 10, or one to about 2, 3, or 4, solvent or water
molecules.
[0034] "Alkyl" refers to an aliphatic hydrocarbon group which can
be straight or branched having 1 to about 60 carbon atoms in the
chain, and which preferably have about 6 to about 50 carbons in the
chain. "Lower alkyl" refers to an alkyl group having 1 to about 8
carbon atoms. "Higher alkyl" refers to an alkyl group having about
10 to about 20 carbon atoms. The alkyl group can be optionally
substituted with one or more alkyl group substituents which can be
the same or different, where "alkyl group substituent" includes
halo, amino, aryl, hydroxy, alkoxy, aryloxy, alkyloxy, alkylthio,
arylthio, aralkyloxy, aralkylthio, carboxy, alkoxycarbonyl, oxo and
cycloalkyl. There can be optionally inserted along the alkyl chain
one or more oxygen, silicon, sulfur, or substituted or
unsubstituted nitrogen atoms, wherein the nitrogen substituent is
lower alkyl. "Branched" refers to an alkyl group in which a lower
alkyl group, such as methyl, ethyl, or propyl, is attached to a
linear alkyl chain Exemplary alkyl groups include methyl, ethyl,
i-propyl, n-butyl, t-butyl, n-pentyl, heptyl, octyl, decyl,
dodecyl, tridecyl, tetradecyl, pentadecyl and hexadecyl. Useful
alkyl groups include branched or straight chain alkyl groups of 6
to 50 carbon, and also include the lower alkyl groups of 1 to about
4 carbons and the higher alkyl groups of about 12 to about 16
carbons.
[0035] "Alkenyl" refers to an alkyl group containing at least one
carbon-carbon double bond. The alkenyl group can be optionally
substituted with one or more "alkyl group substituents." Exemplary
alkenyl groups include vinyl, allyl, n-pentenyl, decenyl,
dodecenyl, tetradecadienyl, heptadec-8-en-1-yl and
heptadec-8,11-dien-1-yl.
[0036] "Alkynyl" refers to an alkyl group containing a
carbon-carbon triple bond. The alkynyl group can be optionally
substituted with one or more "alkyl group substituents." Exemplary
alkynyl groups include ethynyl, propargyl, n-pentynyl, decynyl, and
dodecynyl. Useful alkynyl groups include the lower alkynyl
groups.
[0037] "Cycloalkyl" refers to a non-aromatic mono- or multicyclic
ring system of about 4 to about 10 carbon atoms. The cycloalkyl
group can be optionally partially unsaturated. The cycloalkyl group
can be also optionally substituted with an aryl group substituent,
oxo and/or alkylene. Representative monocyclic cycloalkyl rings
include cyclopentyl, cyclohexyl, and cycloheptyl. Useful
multicyclic cycloalkyl rings include adamantyl, octahydronaphthyl,
decalin, camphor, camphane, and noradamantyl.
[0038] "Aryl" refers to an aromatic carbocyclic radical containing
about 6 to about 10 carbon atoms. The aryl group can be optionally
substituted with one or more aryl group substituents, which can be
the same or different, where "aryl group substituent" includes
alkyl, alkenyl, alkynyl, aryl, aralkyl, hydroxy, alkoxy, aryloxy,
aralkoxy, carboxy, aroyl, halo, nitro, trihalomethyl, cyano,
alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acyloxy,
acylamino, aroylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl,
rylthio, alkylthio, alkylene, and --NRR', where R and R' are each
independently hydrogen, alkyl, aryl, and aralkyl. Exemplary aryl
groups include substituted or unsubstituted phenyl and substituted
or unsubstituted naphthyl.
[0039] "Acyl" refers to an alkyl-CO-- group, wherein alkyl is as
previously described. Exemplary acyl groups comprise alkyl of 1 to
about 30 carbon atoms. Exemplary acyl groups also include acetyl,
propanoyl, 2-methylpropanoyl, butanoyl, and palmitoyl.
[0040] "Aroyl" means an aryl-CO-- group, wherein aryl is as
previously described. Exemplary aroyl groups include benzoyl, and
1- and 2-naphthoyl.
[0041] "Alkoxy" refers to an alkyl-O-- group, wherein alkyl is as
previously described. Exemplary alkoxy groups include methoxy,
ethoxy, n-propoxy, i-propoxy, n-butoxy, and heptoxy.
[0042] "Aryloxy" refers to an aryl-O-- group, wherein the aryl
group is as previously described. Exemplary aryloxy groups include
phenoxy and naphthoxy.
[0043] "Alkylthio" refers to an alkyl-S-- group, wherein alkyl is
as previously described. Exemplary alkylthio groups include
methylthio, ethylthio, i-propylthio, and heptylthio.
[0044] "Arylthio" refers to an aryl-S-- group, wherein the aryl
group is as previously described. Exemplary arylthio groups include
phenylthio and naphthylthio.
[0045] "Aralkyl" refers to an aryl-alkyl-- group, wherein aryl and
alkyl are as previously described. Exemplary aralkyl groups include
benzyl, phenylethyl, and naphthylmethyl.
[0046] "Aralkyloxy" refers to an aralkyl-O-- group, wherein the
aralkyl group is as previously described. An exemplary aralkyloxy
group is benzyloxy.
[0047] "Aralkylthio" refers to an aralkyl-S-- group, wherein the
aralkyl group is as previously described. An exemplary aralkylthio
group is benzylthio.
[0048] "Dialkylamino" refers to an --NRR' group, wherein each of R
and R' is independently an alkyl group as previously described.
Exemplary alkylamino groups include ethylmethylamino,
dimethylamino, and diethylamino.
[0049] "Alkoxycarbonyl" refers to an alkyl-O--CO-- group. Exemplary
alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl,
butyloxycarbonyl, and t-butyloxycarbonyl.
[0050] "Aryloxycarbonyl" refers to an aryl-O--CO-- group. Exemplary
aryloxycarbonyl groups include phenoxy- and naphthoxy-carbonyl.
[0051] "Aralkoxycarbonyl" refers to an aralkyl-O--CO-- group. An
exemplary aralkoxycarbonyl group is benzyloxycarbonyl.
[0052] "Carbamoyl" refers to an H.sub.2N--CO-- group.
[0053] "Alkylcarbamoyl" refers to a R'RN--CO-- group, wherein one
of R and R' is hydrogen and the other of R and R' is alkyl as
previously described.
[0054] "Dialkylcarbamoyl" refers to R'RN--CO-- group, wherein each
of R and R' is independently alkyl as previously described.
[0055] "Acyloxy" refers to an acyl-O-- group, wherein acyl is as
previously described.
[0056] "Acylamino" refers to an acyl-NH-- group, wherein acyl is as
previously described.
[0057] "Aroylamino" refers to an aroyl-NH-- group, wherein aroyl is
as previously described.
[0058] "Alkylene" refers to a straight or branched bivalent
aliphatic hydrocarbon group having from 1 to about 30 carbon atoms.
The alkylene group can be straight, branched, or cyclic. The
alkylene group can be also optionally unsaturated and/or
substituted with one or more "alkyl group substituents." There can
be optionally inserted along the alkylene group one or more oxygen,
sulphur, or substituted or unsubstituted nitrogen atoms, wherein
the nitrogen substituent is alkyl as previously described.
Exemplary alkylene groups include methylene (--CH.sub.2--),
ethylene (--CH.sub.2--CH.sub.2--), propylene
(--(CH.sub.2).sub.3--), cyclohexylene (--C.sub.6H.sub.10--),
--CH.dbd.CH--CH.dbd.CH--, --(CF.sub.2).sub.n(CH.sub.2).sub.m--,
wherein n is an integer from about 1 to about 50 and m is an
integer from 0 to about 50,
--(CH.sub.2).sub.n--N(R)--(CH.sub.2).sub.m--, wherein each of m and
n is independently an integer from 0 to about 50 and R is hydrogen
or alkyl, methylenedioxy (--O--CH.sub.2--O--), and ethylenedioxy
(--O--(CH.sub.2).sub.2--O--). An alkylene group can have about 2 to
about 3 carbon atoms and can further have 6-50 carbons.
[0059] "Halo" or "halide" refers to fluoride, chloride, bromide, or
iodide.
[0060] The term "agent" includes without limitation, medicaments,
vitamins, mineral supplements, substances used for the treatment,
prevention, diagnosis, cure or mitigation of disease or illness,
substances that affect the structure or function of the body, or
pro-drugs, which become biologically active or more active after
they have been placed in a predetermined physiological
environment.
[0061] A "bioactive agent" refers to an agent that is capable of
exerting a biological effect in vitro and/or in vivo. The
biological effect can be therapeutic in nature. As used herein,
"bioactive agent" refers also to a substance that is used in
connection with an application that is diagnostic in nature, such
as in methods for diagnosing the presence or absence of a disease
in a patient. The bioactive agents can be neutral or positively or
negatively charged. Examples of suitable bioactive agents include
pharmaceuticals and drugs, cells, gases and gaseous precursors
(e.g., O.sub.2), synthetic organic molecules, proteins, enzymes,
growth factors, vitamins, steroids, polyanions, nucleosides,
nucleotides, polynucleotides, and diagnostic agents, such as
contrast agents for use in connection with magnetic resonance
imaging, ultrasound, positron emission transmography, computed
tomography, or other imaging modality of a patient.
[0062] "Genetic material" refers generally to nucleotides and
polynucleotides, including deoxyribonucleic acid (DNA) and
ribonucleic acid (RNA). The genetic material can be made by
synthetic chemical methodology known to one of ordinary skill in
the art, or by the use of recombinant technology, or by a
combination of the two. The DNA and RNA can optionally comprise
unnatural nucleotides and can be single or double stranded.
"Genetic material" refers also to sense and anti-sense DNA and RNA,
that is, a nucleotide sequence that is complementary to a specific
sequence of nucleotides in DNA and/or RNA.
[0063] The polymers provided herein can be utilized therapeutically
and/or cosmetically. For example, the polymers in any form
described herein can be used to promote healing and/or that inhibit
disease by targeting drug delivery to local and regional areas. The
polymers provided herein can also be used for a variety of
applications including, but not limited to, production of micro-
and nanoparticles, films, coatings, sutures, and orthopedic
materials. Such materials can be used to repair an injured tissue,
organ, bone, or genetic defect. Other uses of the polymers provided
herein include treatment of early, late, or previously treated
malignancies, pretreatment of malignancies or other condition as a
sensitizer to augment therapy of another agent such as with
radiation sensitizers, avoidance of locoregional lymph node
metastasis, augmentation of local wound healing and decrease in
infection, manipulation of structure and abnormal scar formation,
and for the treatment of post-operative pain. In certain
embodiments, the polymers provided herein are used to treat cancer.
For example, the polymers provided herein can be used to treat
various malignancies, e.g., lung, colon, prostate, pancreas, or
breast cancer. For example, when a film carrying one or more
therapeutic agents is utilized to treat a cancer, it can be
stapled, sutured and/or glued in place, e.g., with a cyanoacrylate
resin.
[0064] The polymers provided herein can also be used to deliver any
agent. The agent can be in any pharmaceutically acceptable form,
including pharmaceutically acceptable salts. A large number of
pharmaceutical agents are known in the art and are amenable for use
in the pharmaceutical compositions of the polymeric materials
described herein. Acceptable agents include, but are not limited
to, chemotherapeutic agents, such as radiosensitizers, receptor
inhibitors and agonists or other anti-neoplastic agents; immune
modulators and bioactive agents, such as cytokines, growth factors,
or steroids with or without the co-incorporation of tumor or
pathogen antigens to increase the anti-neoplastic response as a
means of vaccine development; local anesthetic agents; antibiotics;
or nucleic acids as a means of local gene therapy.
[0065] Unless otherwise defined, e.g., as above, all technical and
scientific terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which this
invention belongs. Although methods and materials similar or
equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials
are described below. All publications, patent applications,
patents, and other references mentioned herein are incorporated by
reference in their entirety, unless noted otherwise. In case of
conflict, the present specification, including definitions, will
control. In addition, the materials, methods, and examples are
illustrative only and not intended to be limiting.
[0066] Where reference is made to a URL or other such identifier or
address, it understood that such identifiers can change and
particular information on the internet can come and go, but
equivalent information can be found by searching the internet.
Reference thereto evidences the availability and public
dissemination of such information.
[0067] Standard techniques can be used for chemical syntheses,
chemical analyses, pharmaceutical preparation, formulation and
delivery, and treatment of subjects. Standard techniques can be
used for recombinant DNA, oligonucleotide synthesis, and tissue
culture and transformation (e.g., electroporation, lipofection).
Reactions and purification techniques can be performed, e.g., using
kits according to manufacturer's specifications or as commonly
accomplished in the art or as described herein. The foregoing
techniques and procedures generally are performed according to
conventional methods well known in the art and as described in
various general and more specific references that are cited and
discussed throughout the present specification. See e.g., Sambrook
et al., Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
[0068] Other features and advantages of the invention will be
apparent from the following detailed description, and from the
claims.
BRIEF FIGURE DESCRIPTION
[0069] FIG. 1 is a bar graph showing the number of cells after
treatment with 10-hydroxycamptothecin loaded films, control films
without 10-hydroxycamptothecin, blank films, and
10-hydroxycamptothecin alone.
[0070] FIG. 2 is a bar graph showing the number of cells after
treatment with 10-hydroxycamptothecin loaded films, control films
without 10-hydroxycamptothecin, blank films, and
10-hydroxycamptothecin alone.
[0071] FIG. 3 is a bar graph showing the cytotoxicity of
poly(glycerol-co-caprolactone) nanoparticles.
[0072] FIG. 4 is a bar graph showing the cytotoxicity of
poly(glycerol-co-caprolactone) nanoparticles with 10%
paclitaxel.
[0073] FIG. 5 is a bar graph showing the cytotoxicity of
poly(glycerol-co-caprolactone) nanoparticles with 1%
paclitaxel.
[0074] FIG. 6 is a graph showing the release of
10-hydroxycamptothecin from poly(lauric, myristic, palmitic, or
stearic glycerol carbonate-co-caprolactone) films.
[0075] FIG. 7 is a graph showing 10-hydroxycamptothecin release
from poly(stearic glycerol carbonate-co-caprolactone) films on
pericardium strips.
[0076] FIGS. 8A and 8B are scanning electron micrographs of
10-hydroxycamptothecin-loaded poly(stearic glycerol
carbonate-co-.epsilon.-caprolactone) films; FIG. 8A shows the
surface of the film (scale bar=3 microns), and FIG. 8B shows the
film in cross-section (scale bar=10 microns).
[0077] FIG. 9 is a graph showing particle swelling at various
pHs.
[0078] FIG. 10 is a graph showing the deprotection observed by
absorbance using UV/Vis spectroscopy at a wavelength of 292 nm.
[0079] FIG. 11 is a scanning electron microscope (SEM) image of
nanoparticles.
[0080] FIG. 12 is a graph of the diameter of sugar derived
nanospheres at various pHs.
[0081] FIG. 13 is a bar graph showing tumor volume in response to
chemotherapy-loaded nanoparticles.
[0082] FIG. 14 is a bar graph showing tumor volume in response to
subcutaneous polymer film implantation.
[0083] FIG. 15 is a bar graph showing the percentage of tumor
growth in response to loaded 10-HCPT and unloaded films.
[0084] FIG. 16 is a bar graph showing the anti-cancer activity of
paclitaxel loaded nanoparticles with LLC (lung cancer) cells in
vitro.
[0085] FIG. 17 is a bar graph showing the activity of paclitaxel
loaded nanoparticles with mesothelioma cells in vitro.
[0086] FIG. 18 is a bar graph showing the anti-cancer activity of
paclitaxel loaded nanoparticles with A459 human lung cancer cells
in vitro.
DETAILED DESCRIPTION
[0087] Provided herein are compounds and processes to prepare
polymer based films, particles, gels, and related compositions, and
processes for delivering agents. The following describes the
synthesis of monomer units and the polymerization of those monomer
units. Also provided is the synthesis of polymeric structures that
incorporate therapeutic agents and methods of using such
compositions to treat various diseases and disorders.
[0088] We will first describe vinyl monomers that can be used in
making the new polymers, as well as methods of synthesizing the
monomers. We will then describe methods of preparing and using the
polymers. Then, we will describe the preparation of films and
particles, as well as the incorporation of agents into polymeric
structures. Finally, we will discuss the applications of the
polymers and polymer-agent combinations.
A. Vinyl Monomer Units
[0089] As shown below, various vinyl monomer units are disclosed
herein. These monomer units are used to prepare polymers, as
described in further detail below. Vinyl monomer units include
compounds of Formula I, II, and III:
##STR00013##
where each Q is independently selected from among O, S, Se, or
NH;
[0090] G, or G and Q together, are selected from among:
##STR00014##
or R.sub.1;
[0091] R.sub.1 is selected from among a straight or branched alkyl,
cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl,
arylalkyl, or fluorocarbon chain of 3-50 carbons, wherein each
alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl,
alkylaryl, arylalkyl, or fluorocarbon chain is optionally
substituted internally or terminally by one or more hydroxyl,
hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or
di-substituted amino, thiol, thioester, sulfate, phosphate,
phosphonate, or halogen substituents; or
[0092] R.sub.1 is selected from among poly(ethylene glycol),
poly(ethylene oxide), poly(hydroxyacid)), a carbohydrate, a
protein, a polypeptide, an amino acid, a nucleic acid, a
nucleotide, a polynucleotide, any genetic material, such as a DNA
or RNA segment, a lipid, a polysaccharide, an antibody, a
pharmaceutical agent, or any epitope for a biological receptor;
or
[0093] R.sub.1 is selected from among a photocrosslinkable or
ionically crosslinkable group; or
[0094] R.sub.1 comprises a first group that is convertible to a
second group different from the first group at a pH at or below
about 6.0;
[0095] R.sub.2 is selected from among hydrogen, a straight or
branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl,
arylsilyl, alkylaryl, arylalkyl or fluorocarbon chain of 1-50
carbons, wherein the alkyl, cycloalkyl, aryl, olefin, silyl,
alkylsilyl, arylsilyl, alkylaryl, arylalkyl or fluorocarbon chain
is optionally substituted internally or terminally by one or more
hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide,
amino, mono- or di-substituted amino, thiol, thioester, sulfate,
phosphate, phosphonate, or halogen substituents; and
[0096] R''.sub.2 is selected from among a straight or branched
alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl,
alkylaryl, arylalkyl, or fluorocarbon chain of 1-50 carbons,
wherein the alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl,
arylsilyl, alkylaryl, arylalkyl, or fluorocarbon chain is
optionally substituted internally or terminally by one or more
hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide,
amino, mono- or di-substituted amino, thiol, thioester, sulfate,
phosphate, phosphonate, or halogen substituents.
[0097] In certain embodiments, a compound of Formula II is selected
from among a compound shown below:
##STR00015##
where R''.sub.2 and G are independently selected as defined
herein.
[0098] In certain embodiments, the compound of Formula II is a
compound of Formula IV, where Q is oxygen. In certain embodiments,
the compound of Formula II is a compound of Formula V, where Q is
sulfur. In certain embodiments, the compound of Formula II is a
compound of Formula VI, where Q is Se. In certain embodiments, the
compound of Formula II is a compound of Formula VII, where Q is
NH.
[0099] In other embodiments, a compound of Formula III is selected
from among a compound Formula VIII, IX, X, or XI, as shown above.
In certain embodiments, the compound of Formula III is a compound
of Formula VIII where Q is oxygen. In certain embodiments, the
compound of Formula III is a compound of Formula IX, where Q is
sulfur. In certain embodiments, the compound of Formula III is a
compound of Formula X, where Q is Se. In certain embodiments, the
compound of Formula III is a compound of Formula XI, where Q is
NH.
[0100] In other embodiments, a compound of Formula II is selected
from among a compound Formula XII, XIII, or XIV, as shown
below:
##STR00016##
where R''.sub.2 and G are independently selected as defined
herein.
[0101] In certain embodiments, the compound of Formula II is a
compound of Formula XII. In certain embodiments, the compound of
Formula II is a compound of Formula XIII. In certain embodiments,
the compound of Formula II is a compound of Formula XIV.
[0102] A compound of Formula III can also be independently selected
from among a compound of Formula XV, XVI, or XVII, as shown
above.
[0103] In certain embodiments, each G group is selected from among
a group shown below:
##STR00017##
where each Q is independently selected from among O, S, Se, or
NH;
[0104] R.sub.3 is selected from among hydrogen, methoxy, ethoxy,
amino, a straight or branched alkyl, cycloalkyl, aryl, olefin,
silyl, alkylsilyl, arylsilyl, alkylaryl, or arylalkyl chain of 1-10
carbons;
[0105] R.sub.4 and R.sub.5 are each independently selected from
among a straight or branched alkyl, cycloalkyl, aryl, olefin,
silyl, alkylsilyl, arylsilyl, alkylaryl, or arylalkyl chain of 1-10
carbons; and
[0106] R.sub.7 is selected from among hydrogen, a straight or
branched alkyl, cycloalkyl, aryl, olefin, alkylaryl, or arylalkyl
chain of 1-50 carbons, wherein the alkyl, cycloalkyl, aryl, olefin,
alkylaryl, or arylalkyl chain is optionally substituted internally
or terminally by one or more hydroxyl, hydroxyether, carboxyl,
carboxyester, carboxyamide, amino, mono- or di-substituted amino,
thiol, thioester, sulfate, phosphate, phosphonate, or halogen
substituents.
[0107] In certain embodiments, each G group is selected from among
a group shown below:
##STR00018##
where each Q, R.sub.4, and R.sub.5 are each independently selected
as defined herein.
[0108] In certain embodiments, each G group is selected from among
a group shown below:
##STR00019##
[0109] where each Q, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and
R.sub.7 are selected as defined herein;
[0110] R.sub.6 is selected from among a straight or branched alkyl,
cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl,
or arylalkyl chain of 1-10 carbons; and
[0111] R.sub.8 is selected from among hydrogen, a straight or
branched alkyl, cycloalkyl, aryl, olefin, alkylaryl, or arylalkyl
chain of 1-50 carbons, wherein the alkyl, cycloalkyl, aryl, olefin,
alkylaryl, or arylalkyl chain is optionally substituted internally
or terminally by one or more hydroxyl, hydroxyether, carboxyl,
carboxyester, carboxyamide, amino, mono- or di-substituted amino,
thiol, thioester, sulfate, phosphate, phosphonate, or halogen
substituents.
[0112] In certain embodiments, each G group is selected from among
a group shown below:
##STR00020##
where each Q, R.sub.2, R.sub.4, and R.sub.5 are independently
selected as defined herein.
[0113] In certain embodiments, R.sub.2 of Formula I is selected
from among hydrogen, C.sub.1-C.sub.20 alkyl, cycloalkyl,
alkylcycloalkyl, aryl, and heteroaryl. In certain embodiments,
R.sub.2 of Formula I is selected from among C.sub.1-C.sub.20 alkyl,
cycloalkyl, aryl, and heteroaryl. In certain embodiments, the
R.sub.2 of Formula I is selected from among any group shown
below:
##STR00021##
[0114] In certain embodiments, R.sub.2 of Formula I is selected
from among, C.sub.1-C.sub.20 alkyl, C.sub.1-C.sub.20 haloalkyl,
heteroalkyl, cycloalkyl, alkylcycloalkyl, aryl, and heteroaryl,
wherein the alkyl, haloalkyl, heteroalkyl, cycloalkyl,
alkylcycloalkyl, aryl, and heteroaryl are optionally substituted.
In certain embodiments, R.sub.2 of Formula I is selected from among
C.sub.1-C.sub.20 alkyl, wherein the alkyl is optionally substituted
with halo, OH, NH.sub.2, NH(CH.sub.3), N(CH.sub.3).sub.2, or COOH.
In certain embodiments, the R.sub.2 of Formula I is selected from
among any group shown below:
##STR00022##
B. Methods of Synthesizing Vinyl Monomer Units
[0115] As shown below, the vinyl monomer units described herein
can, e.g., be synthesized by reacting a compound of Formula I' to
provide a compound of Formula I:
##STR00023##
where each Q, G, or Q and G together, and R.sub.2 are independently
selected as defined herein;
[0116] and LG is a leaving group such as Cl or Br.
[0117] In one embodiment, a compound of Formula HQG, where Q and G
are as defined herein, is dissolved in a solvent such as hexane,
benzene, toluene, diethyl ether, chloroform, ethyl acetate,
dichloromethane, 1,4-dioxane, tetrahydrofuran (THF), acetone,
acetonitrile (MeCN), dimethylformamide (DMF), dimethyl sulfoxide,
acetic acid, n-butanol, isopropanol, n-propanol, ethanol, methanol
or water. In certain embodiments, a compound of Formula HQG is
dissolved in THF. To this solution is added an acryloyl halide,
such as methacryloyl chloride. In certain embodiments a base, such
as a trialkyl amine (e.g. triethylamine), is added to the reaction
mixture. The resulting product is a compound of Formula I.
[0118] In another embodiment, a compound of Formula I is prepared
by reacting a compound of Formula HQG, where Q and G are defined as
above, with an acryl anhydride, such as methacrylic anhydride, in
the presence of a base, such as triethyl amine.
C. Methods of Polymerizing Vinyl Monomer Units
[0119] As shown below, a compound of Formula I can be polymerized
to yield a compound of Formula XX:
##STR00024##
where each Q, G, or G and Q together, and R.sub.2 are independently
selected as defined herein;
[0120] and n is an integer from 2-750; and
[0121] each polymeric terminal group is selected from among amines,
thiols, amides, phosphates, sulphates, hydroxides, alkenes, and
alkynes.
[0122] Any method of vinyl polymerization known in the art can be
used for this reaction. For example, a compound of Formula I can be
reacted with a free-radical initiator. Free-radical initiators
include halogen molecules, such as Cl.sub.2, azo compounds, such as
2,2'-azobis(2-methylpropionitrile) (AIBN), and organic peroxides,
such as di-t-butylperoxide. The polymerization can also be induced
by light and a photoinitiator.
[0123] In one embodiment, a compound of Formula I is dissolved in a
solvent, such as hexane, benzene, toluene, diethyl ether,
chloroform, ethyl acetate, dichloromethane, 1,4-dioxane,
tetrahydrofuran (THF), acetone, acetonitrile (MeCN),
dimethylformamide (DMF), or dimethyl sulfoxide, and reacted with
AIBN to yield a compound of Formula XX.
[0124] In certain embodiments, the polymer of Formula XX is
hydrophobic and contains a pH sensitive group. G groups that are pH
sensitive can be selected from among the groups described herein.
As shown above, polymers of Formula XXI can be obtained by acid
catalyzed hydrolysis from polymers of Formula XX, which contain a
pH sensitive group. Any method of acid catalyzed hydrolysis known
in the art can be used for this transformation. For example, the
hydrolysis can be realized by immersing the polymer of Formula XX
into a hydrochloric acid solution. The pH of the solution can be
between 0.1 and 6.5. In other embodiments, the pH of the solution
is between 1 and 5. For example, the pH can be below about 6.0,
5.5, 5.0, 4.5 or 4.0. In certain embodiments, the pH around 4. In
other embodiments, the pH sensitive group can be removed under
basic conditions and/or can be cleaved enzymatically.
[0125] As shown above, the hydrophilic polymer of Formula XXI can
increase in size as compared to the hydrophobic polymer of Formula
XX. The increased size (S.sub.2) can be between 1.5 and 20 or more
times the original size (S.sub.1). In certain embodiments, the
change in size from S.sub.1 to S.sub.2 is between 2 and 20 times,
e.g., between 5 and 15, 5 and 10, 2 and 4, or 8 and 10 times, the
original size.
E. Additional Vinyl Monomers, Polymerizations, and Hydrolysis
Conditions
[0126] As shown below, a compound, e.g., compound 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, is polymerized alone or in
combination with another monomer, to form a polymer, e.g., compound
1a, 2a, 3a, 4a, 5a, 6a, 7a, 8a, 9a, 10a, 11a, 12a, 13a, 14a, 15a,
or 16a. Any method of polymerization described herein can be used
for this transformation. For example, compound 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, or 16 can be reacted with a
free-radical initiator, such as 2,2'-azobis(2-methylpropionitrile)
(AIBN). The resulting compound 1a, 2a, 3a, 4a, 5a, 6a, 7a, 8a, 9a,
10a, 11a, 12a, 13a, 14a, 15a, or 16a is generally a hydrophobic
polymer with a pH sensitive group. Any method of acid catalyzed
hydrolysis known in the art can be used to cleave the pH sensitive
group, as described herein. Enzymatic hydrolysis alone, or in
combination with an acidic or basic solution, can also be used to
cleave the group. For example, compound 1a, 2a, 3a, 4a, 5a, 6a, 7a,
8a, 9a, 10a, 11a, 12a, 13a, 14a, 15a, or 16a can be immersed in a
hydrochloric acid solution. The resulting compound 1b, 2b, 3b, 4b,
5b, 6b, 9b, 10b, 11b, 12b, 13b, 14b, 15b, or 16b is a hydrophilic
polymer and can increase in size between 1.5 and 20 or more times
the original size of compound 1a, 2a, 3a, 4a, 5a, 6a, 7a, 8a, 9a,
10a, 11a, 12a, 13a, 14a, 15a, or 16a, respectively. For example,
compound 1a, 2a, 3a, 4a, 5a, 6a, 7a, 8a, 9a, 10a, 11a, 12a, 13a,
14a, 15a, or 16a can be exposed to an acidic solution for various
periods of time. Longer periods of exposure can lead to greater
swelling. Alternative methods of achieving greater growth include
raising the temperature and lowering the pH. The degree to which
the particle swells can be reduced by adding difunctional
crosslinkers. Difunctional crosslinkers include di-acrylate species
and provide crosslinking between polymer chains that further
restrict the size of the particle upon expansion.
[0127] Compounds 1, 2, 3, and 4 individually are polymerized to
form a polymer, e.g., compound 1a, 2a, 3a, and 4a, as shown
below:
##STR00025## ##STR00026##
where each Q, n, R.sub.2, R.sub.3, R.sub.7, and terminal group are
independently selected as defined herein.
[0128] Compounds 5 and 6 are individually polymerized to form a
polymer, e.g., compound 5a and 6a, as shown below:
##STR00027##
where each Q, n, R.sub.2, R.sub.4, R.sub.5, and terminal group are
independently selected as defined herein.
[0129] Compound 7 and 8 are individually polymerized to form a
polymer, e.g., compound 7a and 8a, as shown below:
##STR00028##
where each Q, n, R.sub.2, R.sub.4, R.sub.5, and terminal group are
independently selected as defined herein.
[0130] Compounds 9 and 10 are individually polymerized to form a
polymer, e.g., compound 9a and 10a, as shown below:
##STR00029##
where each Q, n, R.sub.2, R.sub.4, R.sub.5, and terminal group are
independently selected as defined herein.
[0131] Compounds 11 and 12 are individually polymerized to form a
polymer, e.g., compound 11a and 12a, as shown below:
##STR00030##
where each Q, n, R.sub.2, R.sub.4, R.sub.5, R.sub.6, and terminal
group are independently selected as defined herein.
[0132] Compounds 13 and 14 are individually polymerized to form a
polymer, e.g., compound 13a and 14a, as shown below:
##STR00031##
where each Q, n, R.sub.2, R.sub.4, R.sub.5, and terminal group are
independently selected as defined herein.
[0133] Compounds 15 and 16 are individually polymerized to form a
polymer, e.g., compound 15a and 16a, as shown below:
##STR00032##
where each Q, n, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7,
R.sub.8, and terminal group are independently selected as defined
herein.
F. Vinyl Homopolymers and Copolymers
[0134] Provided herein are homopolymers prepared by polymerizing a
compound of Formula I. In some embodiments, compounds of Formula I
can be co-polymerized with any vinyl monomer described herein or
known in the art. For example, Compound 1 can be co-polymerized
with Compound 2. Compound 3 can be co-polymerized with any vinyl
monomer known in the art, for example methyl methacrylate.
[0135] In other embodiments, any compounds of Formula I can be
co-polymerized with any vinyl monomer described herein or known in
the art to produce a random copolymer, a block copolymer,
alternating copolymer, or a graft copolymer using any methods known
in the art.
[0136] In additional embodiments, any compound of Formula I can be
co-polymerized with any vinyl monomer described herein or known in
the art to yield a linear, branched, star, or comb polymer, again,
using any methods known in the art.
[0137] Any ratio of a single monomer relative to another monomer
can be used to form a copolymer. Different ratios of monomer units
impart different physical and chemical properties to the copolymer.
Properties of interest include, but are not limited to, thermal
transition temperature, bulk strength, crystallinity, flexibility,
elasticity, and hydrophobicity. Thus, by varying monomer ratios, it
is possible to afford a copolymer with desired characteristics. For
example, introduction of a bulky hydrophobic side group will make
the polymer more hydrophobic and reduce the rate of hydrolysis.
G. Additional Polymers such as Polyesters, Polyethers, and
Polycarbonates
[0138] The following polyesters, polyethers, polyether-esters,
polyamides, polycarbonates, and polyamino acids can be prepared
according to the description provided below. These polymers can be
used to make the films, particles, gels, and related compositions
described herein, and can be used, e.g., to deliver various agents,
e.g., bioactive agents.
[0139] As shown below, the chemical structures of various new
polymers having Formulas XXI, XXII, XXIII, and XXIV:
##STR00033##
where each Q' is independently selected from among O, S, Se, or
NH;
[0140] G', G.sub.1', and G.sub.2' are each independently selected
from among:
##STR00034##
or R.sub.1; wherein G.sub.1' and G.sub.2' are not the same;
[0141] R.sub.1' is selected from among a straight or branched
alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl,
alkylaryl, arylalkyl or fluorocarbon chain of 3-50 carbons, wherein
the alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl,
alkylaryl, arylalkyl or fluorocarbon chain is optionally
substituted internally or terminally by one or more hydroxyl,
hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or
di-substituted amino, thiol, thioester, sulfate, phosphate,
phosphonate, or halogen substituents; or
[0142] R.sub.1' is selected from among poly(ethylene glycol),
poly(ethylene oxide), poly(hydroxyacid)), a carbohydrate, a
protein, a polypeptide, an amino acid, a nucleic acid, a
nucleotide, a polynucleotide, any DNA or RNA segment, a lipid, a
polysaccharide, an antibody, a pharmaceutical agent, or any epitope
for a biological receptor; or
[0143] R.sub.1' is selected from among a photocrosslinkable or
ionically crosslinkable group; or
[0144] R.sub.1' comprises a first group that is convertible to a
second group different from the first group at a pH at or below
about 6.0;
[0145] R.sub.2' is selected from among hydrogen, a straight or
branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl,
arylsilyl, alkylaryl, arylalkyl, or fluorocarbon chain of 1-50
carbons, wherein the alkyl, cycloalkyl, aryl, olefin, silyl,
alkylsilyl, arylsilyl, alkylaryl, arylalkyl, or fluorocarbon chain
is optionally substituted internally or terminally by one or more
hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide,
amino, mono- or di-substituted amino, thiol, thioester, sulfate,
phosphate, phosphonate, or halogen substituents;
[0146] x and y are each independently selected from an integer of
1-750; and
[0147] each polymeric terminal group is selected from among amines,
thiols, amides, phosphates, sulphates, hydroxides, metals, alkanes,
alkenes, and alkynes.
[0148] Also provided are compounds of Formula XXV and XXVI, as
shown below:
##STR00035##
where each Q', G', x, y, and terminal group are independently
selected as defined herein.
[0149] Also provided are compounds of Formula XXVII, XXVIII, XXIX,
and XXX as shown below:
##STR00036##
where each Q', G', R.sub.2', x, and terminal group are
independently selected as defined herein; and
[0150] a is selected from an integer of 1-25.
[0151] Also provided are compounds of Formula XXXI, XXXII, XXXIII,
XXXIV, and XXXV, as shown below:
##STR00037##
where each Q', G', x, y, and, terminal group are independently
selected as defined; and
[0152] b is selected from an integer of 1-14.
[0153] Also provided are compounds of Formula XXXVI and XXXVII, as
shown below:
##STR00038##
where each Q', G', R.sub.2', x, y, and terminal group are
independently selected as defined;
[0154] and c is selected from an integer of 1-14.
[0155] In certain embodiments, the G' of Formula XXI-XXXVII is
selected from among any group shown below:
##STR00039##
where each Q' and R.sub.1' are independently selected as defined
herein.
[0156] In certain embodiments, each R.sub.1', G.sub.1', G.sub.2',
and G' group of any of Formula XXI-XXXVII is independently selected
from among a group shown below:
##STR00040##
[0157] In certain embodiments, each R.sub.1', G.sub.1', G.sub.2',
and G' group of any of Formula XXI-XXXVII is independently selected
from among a group shown below:
##STR00041##
[0158] In certain embodiments, each R.sub.1', G.sub.1', G.sub.2',
and G' group of any of Formula XXI-XXXVII is independently selected
from among a group as shown below:
##STR00042##
where each Q' is independently selected from among O, S, Se, or
NH.
[0159] In certain embodiments, each R.sub.1', G.sub.1', G.sub.2',
and G' group of any of Formula XXI-XXXVII is independently selected
from among a group as shown below:
##STR00043##
where each Q' is independently selected from among O, S, Se, or
NH.
[0160] In certain embodiments, each R.sub.1', G.sub.1', G.sub.2',
and G' group of any of Formula XXI-XXXVII is independently selected
from among a group as shown below:
##STR00044##
where each Q' is independently selected from among O, S, Se, or
NH.
[0161] In certain embodiments, each R.sub.1', G.sub.1',
G.sub.2.sup.1, and G' group of any of Formula XXI-XXXVII is
independently selected from among a group as shown below:
##STR00045##
where each Q' is independently selected from among O, S, Se, or
NH.
[0162] In certain embodiments, each R.sub.1', G.sub.1', G.sub.2',
and G' group of any of Formula XXI-XXXVII is independently selected
from among a group as shown below:
##STR00046##
[0163] Also provided is compound of Formula XXXVIII, as shown
below:
##STR00047##
where each Q', G', x, y, and terminal group is independently
selected as defined herein; and e is selected from an integer of
2-8.
[0164] In various embodiments, the compounds of Formula XXXVIII can
be a random copolymer, a block copolymer, alternating copolymer, or
a graft copolymer.
[0165] In one embodiment, the compound of Formula XXXVIII is a
compound of Formula XXXIX, as shown below:
##STR00048##
where each Q', G', x, y, and terminal group are independently
selected as defined herein.
[0166] In certain embodiments, the compound of Formula XXXVIII is
selected from among a compound of Formula XL, XLI, XLII, or XLIII,
as shown below:
##STR00049##
where each G', x, y, and terminal group are independently selected
as defined herein.
[0167] In certain embodiments, a compound of Formula XXXVIII is
selected from among a compound of Formula XL where Q' is oxygen. In
certain embodiments, a compound of Formula XXXVIII is selected from
among a compound of Formula XLI where Q' is sulfur. In certain
embodiments, a compound of Formula XXXVIII is selected from among a
compound of Formula XLII, where Q' is Se. In certain embodiments, a
compound of Formula XXXVIII is selected from among a compound of
Formula XLIII, where Q' is NH.
[0168] In certain embodiments, the compound of Formula XXXVIII is
selected from among a compound of Formula XLIV, XLV, or XLVI, as
shown below:
##STR00050##
where each G', x, y, and terminal group are independently selected
as defined herein.
[0169] In certain embodiments, a compound of Formula XXXVIII is
selected from among a compound of Formula XLIV. In certain
embodiments, a compound of Formula XXXVIII is selected from among a
compound of Formula XLV. In certain embodiments, a compound of
Formula XXXVIII is selected from among a compound of Formula
XLVI.
H. Synthesis of Polymers of Formulas XXI-XLVI
[0170] Any method of polymerization can be used to produce the
polymers of Formulas XXI-XLVI. For example, polymers of Formulas
XXI-XLVI can be prepared by step-reaction polymerization,
ring-opening polymerization, or by chain-reaction addition
polymerization. As shown below, a polymer of Formula XXXVIII can be
prepared by ring-opening polymerization of a lactone monomer and a
carbonate monomer. The product of this reaction is a polymer of
Formula XXXVIII where Q' is 0, and G' is benzyl.
##STR00051##
where x, y, e, and terminal group are independently selected as
defined herein.
[0171] Any method of ring opening polymerization can be used for
this reaction. For example, the ring opening polymerization may be
induced by heating the reaction. In one embodiment, the reaction is
catalyzed by a metal catalyst, such as Sn(oct).sub.2. The reaction
can be performed neat, or in the presence of a solvent, such as
toluene, dichloromethane, or diethyl ether. Any ratio of monomers
can be used. For example, the ratio of carbonate monomer to lactone
monomer can be 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or
1:19.
[0172] Any lactone can be used for the polymerization shown above.
As shown below, the lactone can be a four, five, six, or seven
membered ring:
##STR00052##
where x, y, e, and terminal group are independently selected as
defined herein.
[0173] As shown above, Compound 17 is prepared by polymerizing a
benzyloxy glycerol carbonate with oxetan-2-one. Compound 18 is
prepared by polymerizing a benzyloxy glycerol carbonate with
dihydrofuran-2(3H)-one. Compound 19 is prepared by polymerizing a
benzyloxy glycerol carbonate with tetrahydro-2H-pyran-2-one.
Compound 20 is prepared by polymerizing a benzyloxy glycerol
carbonate with oxepan-2-one.
I. Chemical Modifications of Polymers of Formulas XXI-XLVI
[0174] Polymers of Formulas XXI-XLVI, wherein G' is a protecting
group, can be further modified to contain various side chains and
pendant groups. For example, G' can be any protecting group known
in the art. In some embodiments, G' is a benzyl ether or
benzylidene protecting group. Any method known in the art of adding
a side chain or pendant group to a polymer can be used to modify
the polymers of Formulas XXI-XLVI. for example, a polymer of
Formulas XXI-XLVI can be modified to contain a side group selected
from among a straight or branched alkyl, cycloalkyl, aryl, olefin,
silyl, alkylsilyl, arylsilyl, alkylaryl, arylalkyl or fluorocarbon
chain of 3-50 carbons, wherein the alkyl, cycloalkyl, aryl, olefin,
silyl, alkylsilyl, arylsilyl, alkylaryl, arylalkyl or fluorocarbon
chain is optionally substituted internally or terminally by one or
more hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide,
amino, mono- or di-substituted amino, thiol, thioester, sulfate,
phosphate, phosphonate, or halogen substituents.
[0175] Other side chain groups can be selected from among
poly(ethylene glycol), poly(ethylene oxide), poly(hydroxyacid), a
carbohydrate, a protein, a polypeptide, an amino acid, a nucleic
acid, a nucleotide, a polynucleotide, any DNA or RNA segment, a
lipid, a polysaccharide, an antibody, a pharmaceutical agent, or
any epitope for a biological receptor. Additionally, a functional
side chain can be incorporated into a polymer of any one of
Formulas XXI-XLVI, such as a photocrosslinkable or ionically
crosslinkable group.
[0176] One method of modifying a polymer of Formula XXXVIII is
shown below. The benzyl ether can be cleaved to afford a hydroxyl
group. Any method of cleaving a benzyl ether known in the art can
be used for this transformation. For example, the benzyl ether can
be cleaved by catalytic hydrogenation. The resulting hydroxyl group
can be reacted with reactants or reagents to produce the polymer of
Formula XXXVIII with a non-hydrogen G' group. Any method of
reacting an alcohol known in the art can be used for this
transformation.
##STR00053##
In the compounds shown above x, y, e, and the terminal group are
independently selected as defined herein.
[0177] As shown below, the polymer of Formula XXXVIII containing a
hydroxyl moiety can be modified to yield a polymer with various G'
groups. For example, the alcohol can be reacted with a carboxylic
acid, such as stearic acid, oleic acid, or myristic acid. In other
embodiments, the alcohol is reacted with 6-benzyloxy-hexanoic acid,
hexanedioic acid monobenzyl ester, or fmoc-6-amino-hexanoic acid.
In various embodiments, the G' group is a carbonate, an ester, or
an ether.
##STR00054##
In the compounds shown above x, y, e, and the terminal group are
independently selected as defined herein; and g is selected from an
integer of 1-25.
[0178] As shown below, a polymer containing a hydroxyl moiety can
be modified to produce a polymer with various groups. For example,
the alcohol can be reacted with a carboxylic acid, such as stearic
acid, oleic acid, or myristic acid. In other embodiments, the
alcohol is reacted with a benzyloxy-alkyl acid, a alkyl acid
monobenzyl ester, or a protected amino-alkyl acid. The benzyloxy,
monobenzyl, and fmoc protecting groups can be removed by methods
known in the art to produce an alcohol, a carboxylic acid, or an
amine, respectively.
##STR00055##
In the compounds shown above x, y, e, g, and the terminal group are
independently selected as defined herein.
J. Methods of Forming Particles and Films
[0179] Various types of films and particles can be formed from
polymers of Formulas XX-XLVI. As shown below, various types of
films and particles, such as micro- or nanoparticles, can be made
from polymers of Formula XX and XXXVIII. Any of the polymeric films
and particles described herein can be made to incorporate
bioactive, e.g., therapeutic, agents within the polymer structure
to produce a polymer/agent complex. Any method known in the art can
be used to form a polymer/agent complex from the monomers and
polymers described herein.
##STR00056##
In the compounds shown above, each Q, Q', G, G', n, R.sub.2, x, y,
e, and terminal group are independently selected as defined
herein.
[0180] Methods of Making Films
[0181] The polymers described herein can be used to produce films
using techniques known in the art. For example, as shown above, a
polymer of Formula XX or XXXVIII is dissolved in an organic
solvent, e.g., dichloromethane, tetrahydrofuran, toluene, or an
aqueous solution and deposited onto a solid surface, such as a
glass surface. In certain embodiments, the polymer is dissolved in
a solvent along with an agent, such as 10-hydroxycamptothecin, and
deposited onto a solid surface, such as a glass surface. The
solvent is then allowed to evaporate to afford a polymeric film
either at ambient temperature or pressure, or at elevated or
reduced temperatures and/or pressures. In certain embodiments, the
polymer solution is deposited onto the solid surface using a
syringe, e.g., a microsyringe. In other embodiments, the polymer
solution is deposited onto the solid surface, e.g., glass, mica,
polymer, collagen, pericardium, TEFLON.RTM., metal, metal alloy,
ceramic or an oxide, using a spraying device, such as an aerosol
device. For example, films containing a polymer of Formula XX or
XXXVIII can be formed by dissolving the polymer in an organic or
aqueous solution, or a mixture of organic and aqueous solutions,
and applying the solution to a surface.
[0182] In other embodiments, films containing a polymer of Formula
XX or XXXVIII are formed by melting the polymer. The melted polymer
can be applied to a solid surface, such as glass. In other
embodiments, the polymer is applied to a solid surface and is then
melted to form a polymeric film.
[0183] In certain embodiments, multi-layered films are prepared.
For example, a polymer is deposited onto a solid surface as
described above to produce a film. A second polymeric solution is
then deposited onto the first film. Polymer films of 1, 2, 3, 4, 5,
and 6, or more layers can be produced by this method. In other
embodiments, each polymer film is produced from a polymer of
Formula XX or XXXVIII. In another embodiment, 1, 2, or 3 of the
layers include a polymer of Formula XX or XXXVIII, and either 1, 2,
or 3 other layers include a different polymer, such as poly(lactic
acid), poly(glycolic acid), poly(lactic-co-glycolic acid),
polycaprolactone, poly(trimethylene carbonate), polyester,
polycarbonate, or polyamide.
[0184] The various layers or fillers can be selected to dissolve or
biodegrade at different rates to produce devices in which different
agents are included in different layers and are released at
different rates. For example, a first agent can be included in a
first surface layer designed to provide a rapid release, e.g.,
within a few hours or days, and a second agent can be included in a
second layer designed to provide an extended release profile, e.g.,
1 week, 2, 3, 4, 5 weeks, or even more. Alternatively, an other
surface layer can be designed not to release any agent, but to
merely delay release of agents in subsequent layers.
[0185] In certain embodiments, a patterned polymer film is prepared
by using a microprinter or a microsyringe. For example, a
microprinter or microsyringe can be used to deposit a solution
containing a polymer of Formula XX or XXXVIII onto a solid surface,
such as a glass surface. The microprinter or microsyringe deposits
the solution in a controlled manner to form patterns such as
stripes and/or dots. The solvent is removed by evaporation. This
method can be performed with more than one polymer simultaneously.
A solution containing a polymer of Formula XX or XXXVIII and an
agent, such as 10-hydroxycamptothecin, may be deposited onto a
solid surface by this technique to afford a patterned agent
containing film. Such patterned films can deliver agents to
specific biological areas and tissues, as determined by the
specific pattern of agent loaded within a film.
[0186] Methods of Making Particles
[0187] The polymers described herein can be used to produce micro-
or nanoparticles using methods known in the art. For example, a
water in oil emulsion technique is described by Edlund and
co-workers (see Edlund et al., Adv. Polymer Sci., 157:67-112, 2001;
and Wang et al., Chem. Pharm. Bull., (Tokyo) 44:1935, 1996).
Briefly, a polymer is dissolved in dichloromethane using a
vortexing device. In certain embodiments, the polymer is dissolved
in dichloromethane along with an agent, such as paclitaxel. The
solution is placed in a 5% polyvinyl alcohol surfactant and
vortexed (or sonicated using a probe tip sonicator) and stirred for
16 hours to produce microparticles. The microparticles are
collected and washed with distilled/deionized water and
lyophilized.
[0188] To produce nanoparticles, one can for example, use a
miniemulsion polymerization method (see, e.g., Landfester et al.,
Macromolecules, 32:5222-8, 1999). Briefly, a monomer as described
herein and a free-radical initiator (such as Cl.sub.2,
2,2'-azobis(2-methylpropionitrile) (AIBN), or di-t-butylperoxide)
are dissolved in a solvent, such as hexane, benzene, toluene,
diethyl ether, chloroform, ethyl acetate, dichloromethane,
1,4-dioxane, tetrahydrofuran (THF), acetone, acetonitrile (MeCN),
dimethylformamide (DMF), or dimethyl sulfoxide. In certain
embodiments, an agent, such as paclitaxel is also dissolved in the
solvent. The solvent is removed via rotary evaporation until a
viscous mixture remains. The viscous mixture is mixed with a
stabilizing surfactant, such as a solution of sodium dodecyl
sulfate, in a buffer solution. This mixture is sonicated for 1 hour
(1 second pulses with a 2 second delay) with 30 W of power, which
forms the miniemulsion and allows the solvent to evaporate. The
miniemulsion is transferred into a temperature-controlled oil bath
and stirred at 65.degree. C. for 2 hours to initiate the
free-radical polymerization. Optionally, the resulting polymeric
nanospheres are dialyzed, e.g., against 5 mM pH 8 phosphate buffer,
acetate buffer, bicarbonate buffer, or sodium citrate buffer, e.g.,
over two days, to remove excess surfactant and salts.
[0189] Alternatively, nanoparticles can be produced by
photoinitiation. For example, a monomer as described herein can be
dissolved in a solvent, such as hexane, benzene, toluene, diethyl
ether, chloroform, ethyl acetate, dichloromethane, 1,4-dioxane,
tetrahydrofuran (THF), acetone, acetonitrile (MeCN),
dimethylformamide (DMF), or dimethyl sulfoxide. In certain
embodiments, an agent, such as paclitaxel is also dissolved in the
solvent. The solvent is removed via rotary evaporation until a
viscous mixture remains. The viscous mixture is mixed with a
stabilizing surfactant solution, such as sodium dodecyl sulfate, in
a buffer solution. The mixture is then sonicated for 30 minutes (1
second pulses with a 2 second delay) with 30 W of power, forming
the miniemulsion and allowing the solvent to partially evaporate.
Eosin Y and 1-vinyl-2-pyrrolidone are added to the emulsion. The
mixture is then exposed to light from a source such as a mercury
arc lamp while the solution is stirred vigorously. The resulting
particles are stirred overnight while open to the air to allow any
remaining solvent to evaporate. Optionally, the polymeric
nanoparticles are then dialyzed against a buffer solution to remove
excess surfactant and salts.
[0190] Polymeric particles can also be prepared by a precipitation
method. For example, a polymer of Formula XXXVIII is dissolved in a
solvent, such as dichloromethane, along with an agent, such as
paclitaxel. The solution is added to an aqueous surfactant
solution, such as sodium dodecyl sulfate in water. The resulting
mixture is sonicated to produce an emulsion. The mixture is stirred
while open to the atmosphere to evaporate the excess solvent, such
as dichoromethane. The resulting particles are collected and
optionally dialyzed using a membrane with a molecular weight cutoff
to remove excess surfactant.
[0191] In some embodiments, the diameter of the particles formed is
between 1 nm and 50 microns, e.g., between 10 nm and 1 micron,
between 50 nm and 1 micron, between 100 nm and 500 nm, or between 1
and 50 microns.
[0192] Encapsulation of an Agent within Polymeric Particles
[0193] Any method known in the art for encapsulating an agent
within a polymeric particle can be used to form a polymer/agent
complex. For example, an oil emulsion technique is used to form
paclitaxel containing particles of Formula XX. A polymer of Formula
XX can be dissolved in a solvent, such as dichloromethane, in the
presence of an agent, such as paclitaxel. The polymer/paclitaxel
solution is vortexed. A surfactant solution, such as 5% polyvinyl
alcohol, is added to the polymer/paclitaxel solution, and the
resulting solution is vortexed for about 15 minutes followed by
stirring for about 16 hours. The resulting particles are collected,
washed with water, and lyophilized. In certain embodiments, the
encapsulation efficiency of paclitaxel by the particles using this
technique is between 30-99%. In another embodiment, the
encapsulation efficiency of paclitaxel by the particles using this
technique is between 60-75%.
[0194] Agents that can be Incorporated into Polymeric Films and
Particles
[0195] Any agent can be incorporated within the polymer films and
particles described herein. For example, a polymer film or particle
described herein can incorporate a pharmaceutical agent selected
from among (1) nonsteroidal anti-inflammatory drugs (NSAIDs)
analgesics, such as diclofenac, ibuprofen, ketoprofen, and
naproxen; (2) opiate agonist analgesics, such as codeine, fentanyl,
hydromorphone, and morphine; (3) salicylate analgesics, such as
aspirin (ASA) (enteric coated ASA); (4) H.sub.1-blocker
antihistamines, such as clemastine and terfenadine; (5)
H.sub.2-blocker antihistamines, such as cimetidine, famotidine,
nizadine, and ranitidine; (6) anti-infective agents, such as
mupirocin; (7) antianaerobic anti-infectives, such as
chloramphenicol and clindamycin; (8) antifungal antibiotic
anti-infectives, such as amphotericin b, clotrimazole, fluconazole,
and ketoconazole; (9) macrolide antibiotic anti-infectives, such as
azithromycin and erythromycin; (10) miscellaneous beta-lactam
antibiotic anti-infectives, such as aztreonam and imipenem; (11)
penicillin antibiotic anti-infectives, such as nafcillin,
oxacillin, penicillin G, and penicillin V; (12) quinolone
antibiotic anti-infectives, such as ciprofloxacin and norfloxacin;
(13) tetracycline antibiotic anti-infectives, such as doxycycline,
minocycline, and tetracycline; (14) antituberculosis
antimycobacterial anti-infectives such as isoniazid (INH), and
rifampin; (15) antiprotozoal anti-infectives, such as atovaquone
and dapsone; (16) antimalarial antiprotozoal anti-infectives, such
as chloroquine and pyrimethamine; (17) anti-retroviral
anti-infectives, such as ritonavir and zidovudine; (18) antiviral
anti-infective agents, such as acyclovir, ganciclovir, interferon
alpha, and rimantadine; (19) alkylating antineoplastic agents, such
as carboplatin and cisplatin; (20) nitrosourea alkylating
antineoplastic agents, such as carmustine (BCNU); (21)
antimetabolite antineoplastic agents, such as methotrexate; (22)
pyrimidine analog antimetabolite antineoplastic agents, such as
fluorouracil (5-FU) and gemcitabine; (23) hormonal antineoplastics,
such as goserelin, leuprolide, and tamoxifen; (24) natural
antineoplastics, such as aldesleukin, interleukin-2, docetaxel,
etoposide (VP-16), interferon alpha, paclitaxel, and tretinoin
(ATRA); (25) antibiotic natural antineoplastics, such as bleomycin,
dactinomycin, daunorubicin, doxorubicin, and mitomycin; (26) vinca
alkaloid natural antineoplastics, such as vinblastine and
vincristine; (27) autonomic agents, such as nicotine; (28)
anticholinergic autonomic agents, such as benztropine and
trihexyphenidyl; (29) antimuscarinic anticholinergic autonomic
agents, such as atropine and oxybutynin; (30) ergot alkaloid
autonomic agents, such as bromocriptine; (31) cholinergic agonist
parasympathomimetics, such as pilocarpine; (32) cholinesterase
inhibitor parasympathomimetics, such as pyridostigmine; (33)
alpha-blocker sympatholytics, such as prazosin; (34) beta-blocker
sympatholytics, such as atenolol; (35) adrenergic agonist
sympathomimetics, such as albuterol and dobutamine; (36)
cardiovascular agents, such as aspirin (ASA), plavix (Clopidogrel
bisulfate) etc; (37) beta-blocker antianginals, such as atenolol
and propranolol; (38) calcium-channel blocker antianginals, such as
nifedipine and verapamil; (39) nitrate antianginals, such as
isosorbide dinitrate (ISDN); (40) cardiac glycoside
antiarrhythmics, such as digoxin; (41) class I anti-arrhythmics,
such as lidocaine, mexiletine, phenyloin, procainamide, and
quinidine; (42) class II antiarrhythmics, such as atenolol,
metoprolol, propranolol, and timolol; (43) class III
antiarrhythmics, such as amiodarone; (44) class IV antiarrhythmics,
such as diltiazem and verapamil; (45) alpha-blocker
antihypertensives, such as prazosin; (46) angiotensin-converting
enzyme inhibitor (ACE inhibitor) antihypertensives, such as
captopril and enalapril; (47) beta blocker antihypertensives, such
as atenolol, metoprolol, nadolol, and propanolol; (48)
calcium-channel blocker antihypertensive agents, such as diltiazem
and nifedipine; (49) central-acting adrenergic antihypertensives,
such as clonidine and methyldopa; (50) diurectic antihypertensive
agents, such as amiloride, furosemide, hydrochlorothiazide (HCTZ),
and spironolactone; (51) peripheral vasodilator antihypertensives,
such as hydralazine and minoxidil; (52) antilipemics, such as
gemfibrozil and probucol; (53) bile acid sequestrant antilipemics,
such as cholestyramine; (54) HMG-CoA reductase inhibitor
antilipemics, such as lovastatin and pravastatin; (55) inotropes,
such as aminone, dobutamine, and dopamine; (56) cardiac glycoside
inotropes, such as digoxin; (57) thrombolytic agents or enzymes,
such as alteplase (TPA), anistreplase, streptokinase, and
urokinase; (58) dermatological agents, such as colchicine,
isotretinoin, methotrexate, minoxidil, tretinoin (ATRA); (59)
dermatological corticosteroid anti-inflammatory agents, such as
betamethasone and dexamethasone; (60) antifungal topical
antiinfectives, such as amphotericin B, clotrimazole, miconazole,
and nystatin; (61) antiviral topical anti-infectives, such as
acyclovir; (62) topical antineoplastics, such as fluorouracil
(5-FU); (63) electrolytic and renal agents, such as lactulose; (64)
loop diuretics, such as furosemide; (65) potassium-sparing
diuretics, such as triamterene; (66) thiazide diuretics, such as
hydrochlorothiazide (HCTZ); (67) uricosuric agents, such as
probenecid; (68) enzymes such as RNase and DNase; (69)
immunosupressive agents, such as cyclosporine, steroids,
methotrexate tacrolimus, sirolimus, rapamycin; (70) antiemetics,
such as prochlorperazine; (71) salicylate gastrointestinal
anti-inflammatory agents, such as sulfasalazine; (72) gastric
acid-pump inhibitor anti-ulcer agents, such as omeprazole; (73)
H.sub.2-blocker anti-ulcer agents, such as cimetidine, famotidine,
nizatidine, and ranitidine; (74) digestants, such as pancrelipase;
(75) prokinetic agents, such as erythromycin; (76) opiate agonist
intravenous anesthetics such as fentanyl; (77) hematopoietic
antianemia agents, such as erythropoietin, filgrastim (G-CSF), and
sargramostim (GM-CSF); (78) coagulation agents, such as
antihemophilic factors 1-10 (AHF 1-10); (79) anticoagulants, such
as warfarin, heparin, and argatroban; (80) growth receptor
inhibitors, such as erlotinib and gefetinib; (82) abortifacients,
such as methotrexate; (83) antidiabetic agents, such as insulin;
(84) oral contraceptives, such as estrogen and progestin; (85)
progestin contraceptives, such as levonorgestrel and norgestrel;
(86) estrogens such as conjugated estrogens, diethylstilbestrol
(DES), estrogen (estradiol, estrone, and estropipate); (87)
fertility agents, such as clomiphene, human chorionic gonadatropin
(HCG), and menotropins; (88) parathyroid agents such as calcitonin;
(89) pituitary hormones, such as desmopressin, goserelin, oxytocin,
and vasopressin (ADH); (90) progestins, such as
medroxyprogesterone, norethindrone, and progesterone; (91) thyroid
hormones, such as levothyroxine; (92) immunobiologic agents, such
as interferon beta-1b and interferon gamma-1b; (93)
immunoglobulins, such as immune globulin 1M, IMIG, IGIM and immune
globulin IV, IVIG, IGIV; (94) amide local anesthetics, such as
lidocaine; (95) ester local anesthetics, such as benzocaine and
procaine; (96) musculoskeletal corticosteroid anti-inflammatory
agents, such as beclomethasone, betamethasone, cortisone,
dexamethasone, hydrocortisone, and prednisone; (97) musculoskeletal
anti-inflammatory immunosuppressives, such as azathioprine,
cyclophosphamide, and methotrexate; (98) musculoskeletal
nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac,
ibuprofen, ketoprofen, ketorlac, and naproxen; (99) skeletal muscle
relaxants, such as baclofen, cyclobenzaprine, and diazepam; (100)
reverse neuromuscular blocker skeletal muscle relaxants, such as
pyridostigmine; (101) neurological agents, such as nimodipine,
riluzole, tacrine and ticlopidine; (102) anticonvulsants, such as
carbamazepine, gabapentin, lamotrigine, phenyloin, and valproic
acid; (103) barbiturate anticonvulsants, such as phenobarbital and
primidone; (104) benzodiazepine anticonvulsants, such as
clonazepam, diazepam, and lorazepam; (105) anti-parkisonian agents,
such as bromocriptine, levodopa, carbidopa, and pergolide; (106)
anti-vertigo agents, such as meclizine; (107) opiate agonists, such
as codeine, fentanyl, hydromorphone, methadone, and morphine; (108)
opiate antagonists, such as naloxone; (109) beta-blocker
anti-glaucoma agents, such as timolol; (110) miotic anti-glaucoma
agents, such as pilocarpine; (111) ophthalmic aminoglycoside
antiinfectives, such as gentamicin, neomycin, and tobramycin; (112)
ophthalmic quinolone anti-infectives, such as ciprofloxacin,
norfloxacin, and ofloxacin; (113) ophthalmic corticosteroid
anti-inflammatory agents, such as dexamethasone and prednisolone;
(114) ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs),
such as diclofenac; (115) antipsychotics, such as clozapine,
haloperidol, and risperidone; (116) benzodiazepine anxiolytics,
sedatives and hypnotics, such as clonazepam, diazepam, lorazepam,
oxazepam, and prazepam; (117) psychostimulants, such as
methylphenidate and pemoline; (118) antitussives, such as codeine;
(119) bronchodilators, such as theophylline; (120) adrenergic
agonist bronchodilators, such as albuterol; (121) respiratory
corticosteroid anti-inflammatory agents, such as dexamethasone;
(122) antidotes, such as flumazenil and naloxone; (123) heavy metal
antagonists/chelating agents, such as penicillamine; (124)
deterrent substance abuse agents, such as disulfiram, naltrexone,
and nicotine; (125) withdrawal substance abuse agents, such as
bromocriptine; (126) minerals, such as iron, calcium, and
magnesium; (127) vitamin B compounds, such as cyanocobalamin
(vitamin B12) and niacin (vitamin B3); (128) vitamin C compounds,
such as ascorbic acid; (129) vitamin D compounds, such as
calcitriol; (130) vitamin A, vitamin E, and vitamin E compounds;
(131) poisons, such as racin; (132) anti-bleeding agents, such as
protamine; (133) antihelminth anti-infectives, such as
metronidazole; and (134) sclerosants such as talc, alcohol, and
doxycyclin.
[0196] In addition to the foregoing, the following less common
drugs can also be used: chlorhexidine; estradiol cypionate in oil;
estradiol valerate in oil; flurbiprofen; flurbiprofen sodium;
ivermectin; levodopa; nafarelin; and somatropin. Further, the
following drugs can also be used: recombinant beta-glucan; bovine
immunoglobulin concentrate; bovine superoxide dismutase; the
formulation comprising fluorouracil, epinephrine, and bovine
collagen; recombinant hirudin (r-Hir), HIV-1 immunogen; human
anti-TAC antibody; recombinant human growth hormone (r-hGH);
recombinant human hemoglobin (r-Hb); recombinant human mecasermin
(r-IGF-1); recombinant interferon beta-1a; lenograstim (G-CSF);
olanzapine; recombinant thyroid stimulating hormone (r-TSH); and
topotecan. Further still, the following intravenous products can be
used: acyclovir sodium; aldesleukin; atenolol; bleomycin sulfate,
human calcitonin; salmon calcitonin; carboplatin; carmustine;
dactinomycin, daunorubicin HCl; docetaxel; doxorubicin HCl; epoetin
alpha; etoposide (VP-16); fluorouracil (5-FU); ganciclovir sodium;
gentamicin sulfate; interferon alpha; leuprolide acetate;
meperidine HCl; methadone HCl; methotrexate sodium; paclitaxel;
ranitidine HCl; vinblastin sulfate; and zidovudine (AZT).
[0197] Further specific examples of useful pharmaceutical agents
from the above categories include: (a) anti-neoplastics such as
androgen inhibitors, antimetabolites, cytotoxic agents, receptor
inhibitors, and immunomodulators; (b) anti-tussives such as
dextromethorphan, dextromethorphan hydrobromide, noscapine,
carbetapentane citrate, and chlorphedianol hydrochloride; (c)
antihistamines such as chlorpheniramine maleate, phenindamine
tartrate, pyrilamine maleate, doxylamine succinate, and
phenyltoloxamine citrate; (d) decongestants such as phenylephrine
hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine
hydrochloride, and ephedrine; (e) various alkaloids such as codeine
phosphate, codeine sulfate and morphine; (f) mineral supplements
such as potassium chloride, zinc chloride, calcium carbonates,
magnesium oxide, and other alkali metal and alkaline earth metal
salts; (g) ion exchange resins such as cholestryramine; (h)
anti-arrhythmics such as N-acetylprocainamide; (i) antipyretics and
analgesics such as acetaminophen, aspirin and ibuprofen; (j)
appetite suppressants such as phenyl-propanolamine hydrochloride or
caffeine; (k) expectorants such as guaifenesin; (l) antacids such
as aluminum hydroxide and magnesium hydroxide; (m) biologicals such
as peptides, polypeptides, proteins and amino acids, hormones,
interferons or cytokines, and other bioactive peptidic compounds,
such as interleukins 1-18 including mutants and analogues, RNase,
DNase, luteinizing hormone releasing hormone (LHRH) and analogues,
gonadotropin releasing hormone (GnRH), transforming growth
factor-.beta.. (TGF-beta), fibroblast growth factor (FGF), tumor
necrosis factor-alpha & beta (TNF-alpha & beta), nerve
growth factor (NGF), growth hormone releasing factor (GHRF),
epidermal growth factor (EGF), fibroblast growth factor homologous
factor (FGFHF), hepatocyte growth factor (HGF), insulin growth
factor (IGF), invasion inhibiting factor-2 (IIF-2), bone
morphogenetic proteins 1-7 (BMP 1-7), somatostatin,
thymosin-alpha-1, gamma-globulin, superoxide dismutase (SOD),
complement factors, hGH, tPA, calcitonin, ANF, EPO and insulin; (n)
anti-infective agents such as antifungals, anti-virals,
antihelminths, antiseptics and antibiotics; and (m) oxygen,
hemoglobin, nitric or sliver oxide.
[0198] Non-limiting examples of broad categories of useful
pharmaceutical agents include the following therapeutic categories:
anabolic agents, anesthetic agents, antacids, anti-asthmatic
agents, anticholesterolemic and anti-lipid agents, anti-coagulants,
anti-convulsants, anti-diarrheals, antiemetics, anti-infective
agents, anti-inflammatory agents, anti-manic agents,
anti-nauseants, antineoplastic agents, anti-obesity agents,
anti-pyretic and analgesic agents, anti-spasmodic agents,
anti-thrombotic agents, anti-uricemic agents, anti-anginal agents,
antihistamines, anti-tussives, appetite suppressants, biologicals,
cerebral dilators, coronary dilators, decongestants, diuretics,
diagnostic agents, erythropoietic agents, expectorants,
gastrointestinal sedatives, hyperglycemic agents, hypnotics,
hypoglycemic agents, ion exchange resins, laxatives, mineral
supplements, mucolytic agents, neuromuscular drugs, peripheral
vasodilators, psychotropics, sedatives, stimulants, thyroid and
anti-thyroid agents, uterine relaxants, vitamins, and prodrugs.
Examples of specific drugs that can be used include: asparaginase,
bleomycin, busulfan, capecitabine, carboplatin, carmustine,
chlorambucil, cisplatin, cyclophosphamide, cytarabine, dacarbizine,
dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin,
etoposide, floxuridine, fludarabine, fluoruracil, gemcitabine,
hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine,
mechlorethamine, melphalan, mercaptopurine, methotrexate,
mitomycin, mitotane, mitoxantrone, paclitaxel, pentostatin,
plicamycin, premextred procarbazine, rituximabe, streptozocin,
teniposid, thioguanine, thiotepa, vinplastine, vinchristine, and
vinorelbine. The currently preferred drugs for lung cancer
treatment is paclitaxel, pemetrexed, 10-hydrocamptothecin,
irinotecan, erlotinibil/gefetinib or derivates of these
molecules.
[0199] Examples of anticancer, antineoplastic agents are
camptothecins. These drugs are antineoplastic by virtue of their
ability to inhibit topoisomerase I. Camptothecin is a plant
alkaloid isolated from trees indigenous to China and analogs
thereof such as 9-aminocamptothecin, 9-nitrocamptothecin,
10-hydroxycamptothecin, 10,11-methylenedioxycamptothecin,
9-nitro-10,11-methylenehydroxycamptothecin,
9-chloro-10,11-methylenehydroxycamptothecin,
9-amino-10,11-methylenehydroxycamptothecin,
7-ethyl-10-hydroxycamptothecin (SN-38), topotecan, DX-8951,
Lurtotecan (GII147221C), and other analogs (collectively referred
to herein as camptothecin drugs) are presently under study
worldwide in research laboratories for treatment of colon, breast,
and other cancers.
[0200] Additionally, the pharmaceutical agent can be a
radiosensitizer, such as metoclopramide, sensamide or neusensamide
(manufactured by Oxigene); profiromycin (made by Vion); RSR13 (made
by Allos); THYMITAQ.RTM. (made by Agouron), etanidazole or
lobenguane (manufactured by Nycomed); gadolinium texaphrin (made by
Pharmacyclics); BuDR/Broxine (made by NeoPharm); IPdR (made by
Sparta); CR2412 (made by Cell Therapeutic); L1X (made by Terrapin);
agents that minimize hypoxia, and the like.
[0201] The agent can be selected from a biologically active
substance. The biologically active substance can be selected from
the group consisting of peptides, poly-peptides, proteins, amino
acids, polysaccharides, growth factors, hormones, anti-angiogenesis
factors, interferons or cytokines, elements, and pro-drugs. In
useful embodiments, the biologically active substance is a
therapeutic drug or pro-drug, most preferably a drug selected from
the group consisting of chemotherapeutic agents and other
antineoplastics such as paclitaxel, antibiotics, anti-virals,
antifungals, anesthetics, antihelminths, anti-inflammatories, and
anticoagulants. In certain useful embodiments, the therapeutic drug
or pro-drug is selected from the group consisting of
chemotherapeutic agents and other antineoplastics such as
paclitaxel, carboplatin and cisplatin; nitrosourea alkylating
antineoplastic agents, such as carmustine (BCNU); fluorouracil
(5-FU) and gemcitabine; hormonal antineoplastics, such as
goserelin, leuprolide, and tamoxifen; receptor inhibitors such as
erlotinib, gefetinib, sutent or anti-ckit inhibitors, such as
GLEEVEC.RTM.; natural antineoplastics, such as aldesleukin,
interleukin-2, docetaxel, etoposide (VP-16), interferon alpha,
paclitaxel, and tretinoin (ATRA).
[0202] In another embodiment, the biologically active substance is
a nucleic acid sequence. The nucleic acid sequence can be selected
from among any DNA or RNA sequence. In certain embodiments, the
biologically active substance is a DNA sequence that encodes a
genetic marker selected from among luciferase gene,
.beta.-galactosidase gene, resistance, neomycin resistance, and
chloramphenicol acetyl transferase. In certain embodiments, the
biologically active substance is a DNA sequence that encodes a
lectin, a mannose receptor, a sialoadhesin, or a retroviral
transactivating factor. In certain embodiments, the biologically
active substance is a DNA sequence that encodes a RNA selected from
the group consisting of a sense RNA, an antisense RNA, siRNA and a
ribozyme.
[0203] Biologically active agents amenable for use with the new
polymers described herein include, without limitation, medicaments;
vitamins; mineral supplements; substances used for the treatment,
prevention, diagnosis, cure or mitigation of disease or illness; or
substances which affect the structure or function of the body; or
pro-drugs, which become biologically active or more active after
they have been placed in a predetermined physiological environment.
Useful active agents amenable for use in the new compositions
include growth factors, such as transforming growth factors (TGFs),
fibroblast growth factors (FGFs), platelet derived growth factors
(PDGFs), epidermal growth factors (EGFs), connective tissue
activated peptides (CTAPs), osteogenic factors, and biologically
active analogs, fragments, and derivatives of such growth factors.
Members of the transforming growth factor (TGF) supergene family,
which are multifunctional regulatory proteins, are preferred.
Members of the TGF supergene family include the beta-transforming
growth factors (for example, TGF-b1, TGF-b2, and TGF-b3); bone
morphogenetic proteins (for example, BMP-1, BMP-2, BMP-3, BMP-4,
BMP-5, BMP-6, BMP-7, BMP-8, and BMP-9); heparin-binding growth
factors (for example, fibroblast growth factor (FGF), epidermal
growth factor (EGF), platelet-derived growth factor (PDGF), and
insulin-like growth factor (IGF)); inhibins (for example, Inhibin
A, Inhibin B); growth differentiating factors (for example, GDF-1);
and activins (for example, Activin A, Activin B, and Activin
AB).
K. Applications for Polymer/Agent Compositions
[0204] The polymers provided herein can be utilized to promote
healing or treat or inhibit disease by targeting drug delivery to
local and regional areas. The polymers provided herein can also be
used for a variety of applications including, but not limited to,
production of micro- and nanoparticles, films, tissue scaffolding,
coatings, sutures, and orthopedic materials. The polymers can also
be used in various cosmetic applications, such as tissue
augmentation. Such materials can be used to repair an injured
tissue, organ, bone, or genetic defect. Other uses of the polymers
provided herein include treatment of early, late, or previously
treated malignancies or to inhibit recurrence of cancers that have
been surgically removed or locally treated, avoidance of
locoregional lymph node metastasis, augmentation of local wound
healing and decrease in infection, manipulation of structure and
abnormal scar formation, and for the treatment of post-operative
pain.
[0205] In some embodiments, the polymers provided herein are used
to treat cancer. For example, the polymers provided herein can be
used to treat lung, colon, prostate, pancreas, or breast cancer.
They could also be used with bone marrow transplantation to target
residual tumor cells in the graft, such as lympohomas and
leukemias. The polymeric particles can be injected or infused into
or around inoperable tumors to locally deliver drugs, such as
chemotherapy or sensitizers, or injected or infused near the site
of the operation incision to deliver agents such as antibiotics,
anesthetics, or growth or healing factors, thereby avoiding side
effects associated with systemic delivery. The polymeric particles
provided herein can be administered at a site of surgery with the
intent of the particles being carried by the lymph fluid to
locoregional nodes. The particles can become trapped at the lymph
nodes, allowing delivery of agents to tumor cells that also
commonly migrate to lymph nodes. Cells that commonly migrate to
lymph nodes include tumor cells and immune cells such as T cells or
dendritic cells, and thus direct presentation of antigen by the
particles can be utilized to enhance the immune system. Thus, the
particles can be used to treat tumors systemically either by
targeting the tumor cells directly or by upregulating the immune
system to fight the tumor.
[0206] The polymeric particles and films provided herein can also
be administered to sites where tumor regrowth is likely to occur.
The particles and films can be administered to areas where, as a
consequence of disease, such as COPD or inflammatory bowl disease,
or systemic chemotherapy, poor healing will result in major
complications. In addition, the particles and films can be
administered to the margins of a surgical excision or resection, or
to sites following local ablative therapy. For such applications,
the polymeric particles are prepared to adhere to the surgical
margin or be retained within the confines and perimeter of the
mass. In other embodiments, the particles or films adhere to the
pericardium, cartilage, or collagen for the delivery of anti-cancer
or antineoplastic agents. In other embodiments, the films can be
stapled, sutured, and/or glued in place at a site.
[0207] In other embodiments, the films and particles described
herein can be used in cosmetic applications. In such an
application, the swelling associated with pH changes can be
advantageously utilized. For example, many of the acrylate polymers
described herein upon delivery to a tissue site swell and increase
in size and bulk, filling voids. Such polymers can be used without
any agents to fill wrinkles or to increase the size of tissue,
e.g., in the lips or cheeks. Optionally, the polymers could deliver
cosmetic agents such as BOTOX.RTM. and/or analgesics. The net
result of such a treatment could be, e.g., a smoothing of facial
tissue. In some embodiments, the polymers used for such an
application are, e.g., 2a-6a and 9a and 10a.
[0208] Any method of adhering particles to biological tissue can be
used for this application. For example, the polymeric particles
provided herein can be coated with Pluronic F 127. In another
embodiment, the particles are entrapped within a gel, hydrogel,
adhesive, sealant or surgical reinforcement strip made from
pericardium, TEFLON.RTM., plastic, or other materials or particles
that can utilize a specific bound such as biotin-avidin to increase
there resident time at the implant site.
[0209] In addition, other types of surgery can benefit from the use
of the polymeric particles and films described herein. For example,
films and particles that contain antibiotics can be utilized for
local delivery at a surgical site. The release rate of the
antibiotics and/or analgesics can be prolonged to reduce the risk
of post-surgical infection, such as Clostridium difficile
infection. This method provides an alternative to the use and risk
of systemic antibiotics. The films and particles can contain
anesthetics, such as local amide anesthetics, IV narcotics, or
anti-inflammatory agents, such as steroids or NSAIDS, to reduce the
discomfort of patients. The use of such polymeric materials can
reduce morbidity secondary to delirium and constipation, decrease
the length of hospital stays for patients, and reduce overall
health care costs.
[0210] In certain embodiments, the polymeric films and particles
are in contact with aqueous or organic solutions, or combinations
thereof. The aqueous solutions can be selected from among water,
buffered aqueous media, saline, buffered saline, solutions of amino
acids, solutions of sugars, solutions of vitamins, solutions of
carbohydrates or combinations of any two or more thereof. The
organic solutions can be selected from among DMSO, ethanol,
methanol, THF, dichloromethane, DMF, hexane or toluene or
combinations of any two or more thereof.
[0211] The polymeric particles and films can contain genetic
materials, e.g., nucleic acid sequences. Such materials can be used
to transfect cells in vitro, ex vivo, or in vivo. The polymeric
particles and films can contain a receptor recognizing a targeting
moiety, allowing specific entrance into a cell or activation or
inhibition of a cell receptor or subsequent intracellular signaling
or apopototic pathway. Thus, the polymeric materials described
herein can be used to deliver nucleic acid sequences to a cell or
to deliver agents that can be transported to the nucleus of a cell
or effect transcription or translation within a cell, such as
steroids or specific transcription factors.
[0212] The methods of using the polymeric particles and films
described herein can be used separately or they can be combined
with one or more therapies to treat a single patient. For example,
particles containing one type of therapeutic agent can be designed
and delivered in a manner that results in the particles becoming
entrapped at lymph nodes, whereas other particles or films that
contain either the same or a different therapeutic agent can be
applied to surgical margins or suture sites. It should also be
recognized that other agents besides chemotherapeutic agents, e.g.,
cytokines, growth factors, and anti-inflammatory agents, can be
used in these methods and combinations of particles containing a
variety of chemotherapeutic or other agents can be employed to both
kill tumor, foster healing, and decrease pain.
[0213] The polymeric microparticles, nanoparticles, films, gels,
and other polymer forms provided herein can be used for in vitro
and in vivo manipulation of drug release kinetics. Depending upon
the polymer selected, the rate of drug release can be delayed or
immediate. In certain embodiments, the polymers provided herein can
be used for prolonged drug delivery after an initial period of
quiescence to permit surgical healing to occur. In other
embodiments, the polymeric particles provided herein provide a dual
mechanism of delivery where a drug is released from the particles
and the particles swell to destabilize or destroy the cell or
cellular compartment (e.g., endosome). Alternatively, the particles
can swell and become lodged, embedded, or otherwise immobilized at
a certain target location due to the enlarged size of the particle.
For example, swelled particles can become lodged or embedded within
a cavity, node, tubule, bronchus, or capillary and can be used to
occlude blood flow as an embolization agent for bleeding,
arteriovenous malformations, or tumor devascularization or can be
used to prevent airflow to a specific portion of the lung as for
endoscopic lung volume reduction surgery, to cite only two examples
of potential uses of this property. Particle swelling can be
triggered by pH change from an exogenous agent added to the
polymer, a change within a cavity or vessel as can occur in a
ischemic or infected tissue or cavity or within an intracellular
compartment such as an endosome. Such particles can also be
manufactured to release agents that manipulate healing or fibrosis
to facilitate permanent or temporary closure of the occluded lumen
or cavity.
[0214] Certain embodiments of the invention are directed towards
polymeric films that are designed to deliver chemotherapeutic
agents locally at surgical sites, with incorporation into the
resection margin. These films are used, e.g., in the treatment of
cancer patients, where delivering drugs locally has the advantage
of avoiding side effects associated with systemic drug delivery.
These films allow the delivery of agents at local concentrations
that could not otherwise be achieved due to drug toxicity. The
films can release agents at the site of surgery and the released
agents can diffuse to areas of close proximity to the implantation
site and to the site of metastatic tumor growth. The implanted
polymeric films can deliver one or more anti-cancer agents, e.g.,
as described herein, that will act upon cancer or metastatic cells
remaining at the surgical margins after tumor excision is
performed. Thus, the films can reduce the incidence of tumor
recurrence at a resection margin after removal of cancerous
tissue.
[0215] An advantage of the films provided herein is the ability to
cover larger areas uniformly. For example, the polymeric films can
cover the chest wall to treat diseases such as mesothelioma or in
other body cavities for diseases such as sarcomas. In addition, the
polymeric films can incorporate local anesthetics or IV narcotics
and be applied along an entire surgical incision for peri-operative
analgesia, or incorporate growth factors, anti-inflammatory agents
in order to manipulate wound healing and prevent hypertrophic scar
or stricture formation.
[0216] Polymeric films containing a single or multiple agents can
be applied to a solid surface in a controlled manner to form
patterns such as stripes and dots. Single or multiple agents can be
incorporated in any pattern to achieve precise therapeutic delivery
of multiple agents simultaneously. More than one type of polymer
film can be used to further tune or control the release of the
drug. A further embodiment of the invention is the use of
multi-layer films to alter the release of the agent(s).
[0217] For example, a film composed of a polyester-co-carbonate of
80:20 caproic acid and glycerol-stearic acid can be loaded with a
drug, such as taxol, camptothecin, or pemetrexed. The film can then
be coated with another polymer of the same or different composition
that does not contain the drug, forming a multi-layered film. The
top polymer layer, which does not have the drug, acts as a
sacrificial layer that first inhibits the release of the drug from
the underlying film, but as the top layer degrades, the bottom
layer starts to release the drug. In this fashion, delayed and
controlled release can occur and can be utilized to allow initial
wound healing to occur before delivery of chemotherapy which can
inhibit wound healing, as one example. Alternatively, different
drugs can be released sequentially and either enhance or prolong
the effect of the other drug or protect "normal" cells from the
toxic effects of the second drug or to rescue cells from the
effects of a second agent, for example pre-treatment with folate
can limit toxicity of normal cells to anti-folate chemotherapies
and yet tumor cells remain susceptible.
[0218] The polymers provided herein can be used to deliver any
agent. The agent can be in any pharmaceutically acceptable form,
including pharmaceutically acceptable salts. A large number of
pharmaceutical agents are known in the art and are amenable for use
in the pharmaceutical compositions of the polymeric materials
described herein. Acceptable agents are described elsewhere herein,
and include, but are not limited to, chemotherapeutic agents, such
as radiosensitizers, receptor inhibitors and agonists or other
anti-neoplastic agent; immune modulators and bioactive agents, such
as cytokines, growth factors or steroids with or without the
co-incorporation of tumor or pathogen antigens to increase the
anti-neoplastic response as a means of vaccine development; local
anesthetic agents; antibiotics; or nucleic acids as a means of
local gene therapy.
[0219] The biologically active substances and agents are used in
amounts that are therapeutically effective. While the effective
amount of a biologically active substance will depend on the
particular material being used, amounts of the biologically active
substance from about 1% to about 65% can be desirable. Lesser
amounts can be used to achieve efficacious levels of treatment for
certain biologically active substances.
[0220] The amount of drug delivered per area of film or per
particle will depend on the therapeutic range of the drug, its
toxicity when delivered locally, and the clinical characteristics
of the patient being treated. The number of particles or amount of
film delivered to a site is selected depending on factors such as
1) the amount of agent delivered per particle, 2) the therapeutic
range of the agent, 3) the local toxicity of the agent, and 4) the
clinical characteristics of the patient being treated. The
development of dosages based on these parameters is routinely
performed by those skilled in the art of pharmacology and clinical
medicine. For example, between 1.times.10.sup.4 and
1.times.10.sup.9 particles/cm can be administered to a biological
area.
[0221] The release kinetics of a given polymer film or particle can
be fine-tuned and adjusted by varying the ratio of monomer units
and/or by modifying the side chains of a given copolymer. In this
manner, a family of copolymers with varying release kinetics can be
used to accommodate the delivery of several different drugs with
differing desired release kinetics. For example, making more side
chains along the polymer that are hydrophilic will generally make
the polymer more hydrophilic overall and will also generally
increase the release rate of an agent from the polymer.
[0222] In certain embodiments, the polymeric particles or films
delay release of chemotherapeutic agents. The delayed release can
coincide with wound healing. In certain embodiments, drug delivery
is delayed for a period of approximately 0-6 weeks. In other
embodiments, the drug is released over a period of 1-6 weeks. In
another embodiment, the drug is released over a period of 2 weeks.
In other embodiments, the drug is released for up to 3 months. One
method of controlling the rate of release from the particles is by
varying the ratio of different monomer units during polymerization.
For example, a ratio of 20:80 of glycerol and caproic acid provides
polymers and resulting microparticles that release drug over five
days.
[0223] Provided herein are particles, including microparticles and
nanoparticles. In certain embodiments, the size of the polymer
particles described herein are between 2 and 100 nm in diameter. In
other embodiments, the size of the polymer particles are between
0.02-10 micrometers in diameter. In other embodiments, the size of
the polymer particles are between 1-50 micrometers in diameter.
Other polymeric particles of a larger size can be useful at
specific sites, such as where tumor regrowth is prevalent. For
example, polymeric particles of a larger size can be useful at a
surgical margin, where suturing or stapling has occurred, or within
a naive or treated tumor such as an ablated cavity secondary to
radiofrequency ablation or other therapy, or within a spontaneous
cavity such as occurs in squamous cell carcinoma. Placement of
polymeric particles within other spontaneous cavities could be
utilized to result in sclerosis of the cavity, either with release
of specific sclerosing agents such as talc powder, alcohol or
doxycyclin as examples or other inflammatory agents. This approach
can then be utilized in the treatment of bullous disease in
emphysema or infectious diseases such as ecchinococcal cysts, for
example.
[0224] The new monomers and polymers can also be used to prepare
biodegradable oligomers, polymers, macromolecules, and copolymers
using standard techniques. The oligomers, polymers, macromolecules
and copolymers can contain alkyl side chains formed between [1] a
monomer or macromolecular unit containing at least one functional
side group; [2] alkyl chains containing 1-50 carbon units; and, in
certain embodiments, [3] a structurally different monomer or
macromolecular unit. In certain embodiments, the macromolecular
materials can be elastic solids or viscoelastic solids. In various
embodiments, the macromolecular materials provided herein are
hydrophobic or hydrophilic. In other embodiments, a macromolecular
material provided herein undergoes a change from hydrophobic to
hydrophilic in response to a change in pH. In certain embodiments,
the macromolecular materials provided herein swell to a size that
destabilizes or destroys a cell or cellular compartment.
EXAMPLES
[0225] The invention is further described in the following
examples, which do not limit the scope of the invention described
in the claims.
Example 1
Synthesis of
5-Methyl-2-(2,4,6-trimethoxyphenyl)-[1,3]-5-dioxan-5-yl-methyl
methacrylate
##STR00057##
[0227]
5-Methyl-2-(2,4,6-trimethoxyphenyl)-[1,3]-5-dioxan-5-yl-methanol
was prepared according a modification of a previously reported
method (Gillies et al., J Am Chem Soc 126:11936-43, 2004). First,
1,1,1-tris(hydroxymethyl)ethane and 2,4,6-trimethoxybenzaldehyde
were dissolved in tetrahydrofuran, and 5 .ANG. molecular sieves
were added as a desiccant. A catalytic amount of p-toluenesulfonic
acid was then added to the mixture, and the reaction was allowed to
proceed at room temperature. When the reaction was complete,
triethylamine was added to quench the acid. The molecular sieves
were then removed using filtration. The solvent was removed via
rotary evaporation under reduced pressure, and the residue
dissolved in dichloromethane. This mixture was then washed three
times with 100 mM pH 8.0 phosphate buffer and dried over anhydrous
sodium sulfate. The solvent was subsequently removed using rotary
evaporation under reduced pressure, and the residue was purified
using silica gel chromatography.
[0228]
5-Methyl-2-(2,4,6-trimethoxyphenyl)-[1,3]-5-diox-anylmethanol and
triethylamine were dissolved in dichloromethane and chilled to
0.degree. C. Methacryloyl chloride was then added drop wise to the
mixture. After mixing for 16 h, the mixture was then washed three
times with 100 mM pH 8.0 phosphate buffer and dried over anhydrous
sodium sulfate. The solvent was subsequently removed using rotary
evaporation under reduced pressure, and the residue, and the title
compound was isolated using silica gel chromatography.
Example 2
Synthesis of 5-Methyl-2-phenyl-[1,3]-5-dioxanylmethanol
##STR00058##
[0230] 1,1,1-Tris(hydroxymethyl)ethane (2.61 g, 21.7 mmol) and
p-toluenesulfonic acid (0.339 g, 1.97 mmol) were dissolved in
benzaldehyde (2.8 mL, 2.9 g, 28 mmol) and stirred at 45.degree. C.
for 1 h. At this time, toluene (1.0 mL) was added to the solution,
and toluene/water was distilled out of the mixture at 95.degree. C.
Fresh toluene was added, and distillation was carried out again.
This process was repeated until no water was observed in the
distillate. Sodium bicarbonate was added to quench the acid, and
excess sodium bicarbonate was removed using filtration. The
remaining toluene was removed via rotary evaporation, leaving a
slightly yellow oil. This mixture was then separated using silica
gel chromatography. The product was obtained as a white solid at
41.8% yield.
Example 3
Synthesis of 5-Methyl-2-phenyl-[1,3]-5-dioxanylmethyl
Methacrylate
##STR00059##
[0232] 5-Methyl-2-phenyl-[1,3]-5-dioxanylmethanol (0.504 g, 2.42
mmol) and triethylamine (0.68 mL, 0.49 g, 4.8 mmol) were dissolved
in dichloromethane and chilled to 0.degree. C. Methacryloyl
chloride (0.35 mL, 0.37 g, 3.6 mmol) was then added drop wise to
the mixture. After mixing for 16 hours, the mixture was then washed
100 mM pH 8.0 phosphate buffer (50 mL.times.3) and dried over
anhydrous sodium sulfate. The solvent was subsequently removed
using rotary evaporation under reduced pressure, and the product
was isolated using silica gel chromatography at 83.9% yield.
Example 4
Synthesis of 1,3-bis(benzyloxy)propan-2-yl Methacrylate
##STR00060##
[0234] 1,3-bis(benzyloxy)propan-2-ol (0.45 mL, 0.50 g, 1.8 mmol)
and triethylamine (0.52 mL, 0.37 g, 3.7 mmol) were dissolved in
dichloromethane and chilled to 0.degree. C. Methacryloyl chloride
(0.27 mL, 0.29 g, 2.8 mmol) was then added drop wise to the
mixture. After mixing for 16 h, the mixture was then washed 100 mM
pH 8.0 phosphate buffer (50 mL.times.3) and dried over anhydrous
sodium sulfate. The solvent was subsequently removed using rotary
evaporation under reduced pressure, and the product was isolated
using silica gel chromatography at 81.0% yield.
Example 5
Poly(benzyloxy glycerol carbonate-co-.epsilon.-caprolactone)
##STR00061##
[0236] 5-(benzyloxymethyl)-1,3-dioxan-2-one (624 mg, 3 mmol) and
.epsilon.-caprolactone were combined of varying ratios (to a total
of 10.0 mmol) in a 10 mL schlenk flask and subsequently evacuated
and flushed with N.sub.2 three times. Meanwhile, the catalyst
(Sn(oct).sub.2, 6.5 .mu.L, 0.02 mmol, monomer/initiator ratio=500)
was evacuated in a small flask for 60 minutes. The Schlenk flask
was partially submerged in a thermostatted oil bath, preheated to
140.degree. C. Toluene (400 .mu.L) was added to the catalyst and
the mixture was injected via syringe to the monomers. The reaction
was stirred for 48 hours, removed from heat, and cooled to room
temperature. The polymer was dissolved in dichloromethane (10 mL)
and precipitated in cold methanol. The solvent was decanted and
subsequently dried by evaporation. The resulting polymer formed
either a viscous oil or white solid precipitate depending on the
carbonate content of the copolymer. Copolymers were formed with the
following carbonate mole fractions: 0.05, 0.10, 0.20, 0.30, 0.40,
0.50, 1.00.
Example 6
Poly(hydroxy glycerol carbonate-co-.epsilon.-caprolactone)
##STR00062##
[0238] Poly(benzyloxy glycerol carbonate-co-.epsilon.-caprolactone)
(1.0 g, 2.02 mmol) was dissolved in 50 mL dry dichloromethane
inside a Parr bottle. 10% Pd/C (50 mg) and 20% Pd(OH).sub.2/C (50
mg) were then added to the solution. The reaction mixture was
evacuated and purged with hydrogen three times. The flask was then
pressurized to 60 psi with hydrogen and shaken for 24 hours. The
reaction mixture was filtered through Celite and the filter cake
washed with 50 mL dichloromethane. The solvents were then
evaporated to yield the final polymer. The resulting polymer formed
either a viscous oil or white solid precipitate depending on the
carbonate content of the copolymer. Copolymers were formed with the
following carbonate mole fractions: 0.05, 0.10, 0.20, 0.30, 0.40,
0.50, 1.00.
[0239] Table 1 below indicates the composition, molecular weight,
and thermal data of the different copolymers, which are illustrated
by structural formulas below the table. In Table 1,
CL=caprolactone; CG carbonate of glycerol f.sub.cg=mole percent
carbonate monomer in polymerization feed; F.sub.cg=mole percent
carbonate monomer in copolymer; M.sub.n=number average molecular
weight; PDI=polydispersity index; T.sub.g=glass transition
temperature, T.sub.c=crystallization temperature; T.sub.m=melting
temperature; H.sub.f=heat of fusion.
TABLE-US-00001 TABLE 1 Molecular Weights Thermal Properties M.sub.n
M.sub.n M.sub.w/ T.sub.g T.sub.c T.sub.m .DELTA.H.sub.f Polymer
f.sub.cg F.sub.cg (theo.) (SEC) M.sub.n (.degree. C.) (.degree. C.)
(.degree. C.) (J/g) CL-CG-100-0 0 0 57,000 22,700 1.47 -64 36 57
61.5 CL-CG-90-10-Bn 10 11 61,700 13,300 1.67 -54 8 40 38.5
CL-CG-90-10-OH 10 11 57,200 12,200 1.67 -59 7 35 32.6
CL-CG-80-20-Bn 20 23 66,400 10,200 1.96 -49 -4 31 25.4
CL-CG-80-20-OH 20 23 57,400 8,600 1.96 -56 0 23 8.5
CL-CG-80-20-C6-OH 20 23 68,800 10,100 1.91 -47 -1 43 33
CL-CG-80-20-C5-COOH 20 23 70,200 10,400 1.96 -46 -5 40 33
CL-CG-80-20-C6-NH.sub.2 20 23 68,700 10,100 1.94 -44 8 44 35
CL-CG-70-30-Bn 30 30 71,100 9,300 1.78 -43 3 22 13.4 CL-CG-60-40-Bn
40 42 75,800 7,900 1.94 -38 none none none CL-CG-0-100-Bn 100 100
104,000 3,600 3.16 -10 none none none ##STR00063## ##STR00064##
##STR00065## ##STR00066## ##STR00067## ##STR00068## ##STR00069##
##STR00070## ##STR00071## ##STR00072## ##STR00073##
Example 7
Poly(myristic acid carbonate-co-.epsilon.-caprolactone)
##STR00074##
[0241] Poly(benzyloxy glycerol carbonate-co-.epsilon.-caprolactone)
(1.0 g, 2.02 mmol), myristic acid (0.690 g, 3.03 mmol) and
dimethylaminopyridine (DMAP) (0.123 g, 1.01 mmol) were dissolved in
100 mL dry dichloromethane. Dicyclohexylcarbodiimide (DCC) (0.500
g, 2.42 mmol) was added to the reaction mixture and a white
precipitate formed. The mixture was stirred for 24 hours at room
temperature under nitrogen. The precipitate compound was isolated
by filtration and the filtrate was concentrated. The concentrated
filtrate was dissolved in dichloromethane and precipitated in cold
methanol (25 mL) The solvent was decanted and subsequently dried by
evaporation. The resulting polymer was a white solid
precipitate.
Example 8
Poly(stearic acid carbonate-co-.epsilon.-caprolactone)
[0242] Poly(benzyloxy glycerol carbonate-co-.epsilon.-caprolactone)
(1.0 g, 2.02 mmol), stearic acid (0.859 g, 3.03 mmol) and DMAP
(0.123 g, 1.01 mmol) were dissolved in 100 mL dry dichloromethane.
DCC (0.500 g, 2.42 mmol) was added to the reaction mixture and a
white precipitate formed. The mixture was stirred for 24 hours at
room temperature under nitrogen. The precipitate compound was
isolated by filtration and the filtrate was concentrated. The
concentrated filtrate was dissolved in dichloromethane and
precipitated in cold methanol (25 mL). The solvent was decanted and
subsequently dried by evaporation. The resulting polymer was a
white solid precipitate.
Example 9
Poly(oleic acid carbonate-co-.epsilon.-caprolactone)
[0243] Poly(benzyloxy glycerol carbonate-co-.epsilon.-caprolactone)
(250 mg, 0.43 mmol) was dissolved in 25 mL of pyridine and cooled
to 0.degree. C. Oleoyl chloride (183 mg, 0.65 mmol) was added drop
by drop. The mixture was stirred for 24 hours at room temperature
under nitrogen. The pyridine was removed under vacuum, the crude
product was dissolved in dichloromethane, and precipitated in cold
methanol (25 mL). The solvent was decanted and subsequently dried
by evaporation. The resulting polymer was a white solid
precipitate.
Example 10
Amine Functionalized Poly Carbonate of Glycerol-co-caprolactone
##STR00075##
[0245] An amine-derivitized copolymer poly(6-amino-hexanoic acid
2-oxo-1,3-dioxan-5-yl ester-co-.epsilon.-caprolactone) was prepared
using the following methods.
Synthesis of poly(fmoc-6-amino-hexanoic acid 2-oxo-1,3-dioxan-5-yl
ester-co-.epsilon.-caprolactone)
[0246] Fmoc-6-amino-hexanoic acid (0.277 g, 0.78 mol),
poly(5-hydroxy-1,3-dioxan-2-one-co-.epsilon.-caprolactone) (1.5 g,
2.6 mmol, 22 mol % carbonate), DCC (0.129 g, 0.63 mmol), and DMAP
(0.032 g, 0.26 mmol) were dissolved in DCM (20 mL). The solution
was stirred at RT for 18 h. The DCU was filtered and the solvent
evaporated. The product was dissolved in dichloromethane (10 mL)
and precipitated in cold methanol. The solvent was decanted and
subsequently dried by evaporation (85% yield). Addition of the
amine side chain was determined by the presence of the methylene
group nearest the Fmoc protecting group, as well as the Fmoc
protecting group itself, with peaks in the .sup.1H NMR spectrum at
3.10-3.19 (m, 2H, OCH.sub.2), and 4.45 (s, 2H, PhCH.sub.2),
7.24-7.38 (m, 5H, aromatic), respectively.
Deprotection of poly(fmoc-6-Amino-hexanoic acid
2-oxo-1,3-dioxan-5-yl ester-co-.epsilon.-caprolactone)
[0247] The copolymer (300 mg) was dissolved in a 40% mixture of
piperidine (16 mL) and dry dimethyl formamide (24 mL) and the
reaction was stirred for 90 min The solvents were evaporated under
reduced pressure. The product was dissolved in dichloromethane (10
mL) and precipitated in cold methanol. The solvent was decanted and
subsequently dried by evaporation (quantitative yield). Complete
deprotection was determined by the absence of the Fmoc protecting
group peaks in the .sup.1H NMR spectrum at 4.88-4.95 (m, 2H,
CH.sub.2), and 7.24-7.75 (m, 5H, aromatic).
Example 11
Hydroxyl Functionalized Poly Carbonate of
Glycerol-Co-Caprolactone
##STR00076##
[0249] A primary alcohol-derivitized copolymer
poly(6-hydroxy-hexanoic acid 2-oxo-1,3-dioxan-5-yl
ester-co-.epsilon.-caprolactone) was synthesized using the
following steps.
Synthesis of 6-benzyloxy-hexanoic acid
[0250] .epsilon.-caprolactone (10 mL, 0.18 mol), benzyl bromide
(13.4 mL, 0.11 mol), and potassium hydroxide (11.3 g, 0.281 mol)
were dissolved in toluene (200 mL). The reaction flask was placed
in a 120.degree. C. pre-heated oil bath and refluxed overnight
under stirring. The mixture was then neutralized using 1 M HCl (300
mL), the toluene evaporated off, and the product extracted using
dichloromethane (3.times.300 mL) to afford a mixture of mono and
di-protected 6-hydroxy-hexanoic acid. The crude product was
saponificated with 1M sodium hydroxide (200 mL) and methanol (200
mL), extracted with dichloromethane (3.times.200 mL), and the
solvent was evaporated under reduced pressure to afford pure
6-benzyloxy-hexanoic acid (72% yield). .sup.1H NMR (CDCl.sub.3)
1.38-1.46 (m, 2H, CH.sub.2), 1.57-1.68 (m, 4H, CH.sub.2CH.sub.2),
2.32-2.38 (m, 2H, CH.sub.2COOH), 3.42-3.46 (m, 2H, OCH.sub.2),
4.48-4.53 (s, 2H, PhCH.sub.2), 7.27-7.31 (m, 5H, aromatic).
Poly(6-benzyloxy-hexanoic acid 2-oxo-1,3-dioxan-5-yl
ester-co-.epsilon.-caprolactone)
[0251] 6-Benzyloxy-hexanoic acid (0.173 g, 0.78 mmol),
poly(5-hydroxy-1,3-dioxan-2-one-co-.epsilon.-caprolactone) (1.5 g,
2.6 mmol, 22 mol % carbonate), DCC (0.129 g, 0.63 mmol), and DMAP
(0.032 g, 0.26 mmol) were dissolved in DCM (20 mL). The solution
was stirred at RT for 18 h. The DCU was filtered and the solvent
evaporated. The product was dissolved in dichloromethane (10 mL)
and precipitated in cold methanol. The solvent was decanted and
subsequently dried by evaporation (86% yield). Addition of the
alcohol side chain was determined by the presence of the methylene
group nearest the benzyl protecting group, as well as the benzyl
protecting group itself, with peaks in the .sup.1H NMR spectrum at
3.40-3.44 (m, 2H, OCH.sub.2), and 4.48-4.53 (s, 2H, PhCH.sub.2),
7.27-7.31 (m, 5H, aromatic), respectively.
Deprotection of poly(6-benzyloxy-hexanoic acid
2-oxo-1,3-dioxan-5-yl ester-co-.epsilon.-caprolactone)
[0252] The copolymer (300 mg) was dissolved in 50 mL dry
dichloromethane inside a Parr bottle. 10% Pd/C (50 mg) and 20%
Pd(OH).sub.2/C (50 mg) were then added to the solution. The
reaction mixture was evacuated and purged with hydrogen three
times. The flask was then pressurized to 60 psi with hydrogen and
shaken for 24 hours. The reaction mixture was filtered through
Celite and the filter cake washed with 50 mL dichloromethane. The
solvents were then evaporated to yield the final polymer
(quantitative yield). Complete deprotection was determined by the
absence of the benzyl protecting group peaks in the .sup.1H NMR
spectrum at 4.48-4.53 (s, 2H, PhCH.sub.2), 7.27-7.31 (m, 5H,
aromatic).
Example 12
Carboxylic Acid Functionalized Poly Carbonate of
Glycerol-co-caprolactone
##STR00077##
[0254] A carboxylic acid-derivitized copolymer poly(hexanedioic
acid mono-(2-oxo-1,3-dioxan-5-yl) ester-co-.epsilon.-caprolactone)
was synthesized using the following steps.
Synthesis of Hexanedioic Acid Monobenzyl Ester
[0255] DOWEX.RTM. 50W-X2 (2 g), benzyl formate (10 mL, mol), and
adipic acid (2 g, mol) were added to octane (10 mL) The mixture was
refluxed for 4 hours at 100.degree. C., and the crude product was
purified via silica chromatography to yield a clear, colorless
liquid (87% yield). .sup.1H NMR (CDCl.sub.3) 1.59-1.78 (m, 4H,
CH.sub.2CH.sub.2), 2.33-2.39 (m, 4H, CH.sub.2COOH), 5.09 (s, 2H,
PhCH.sub.2), 7.25-7.30 (m, 5H, aromatic).
Poly(hexanedioic acid mono-(2-oxo-1,3-dioxan-5-yl)
ester-co-.epsilon.-caprolactone)
[0256] Hexanedioic acid monobenzyl ester (0.184 g, 0.78 mmol),
poly(5-hydroxy-1,3-dioxan-2-one-co-.epsilon.-caprolactone) (1.5 g,
2.6 mmol, 22 mol % carbonate), DCC (0.129 g, 0.63 mmol), and DMAP
(0.032 g, 0.26 mmol) were dissolved in dichloromethane (20 mL). The
solution was stirred at RT for 18 h. The DCU was filtered and the
solvent evaporated. The product was dissolved in dichloromethane
(10 mL) and precipitated in cold methanol. The solvent was decanted
and subsequently dried by evaporation (83% yield). Addition of the
carboxylic acid side chain was determined by the presence of the
benzyl protecting group, with peaks in the .sup.1H NMR spectrum at
5.06 (s, 2H, PhCH.sub.2), 7.27-7.33 (m, 5H, aromatic).
Deprotection of poly(6-benzyloxy-hexanoic acid
2-oxo-1,3-dioxan-5-yl ester-co-.epsilon.-caprolactone)
[0257] The copolymer (300 mg) was dissolved in 50 mL dry
dichloromethane inside a Parr bottle. 10% Pd/C (50 mg) and 20%
Pd(OH).sub.2/C (50 mg) were then added to the solution. The
reaction mixture was evacuated and purged with hydrogen three
times. The flask was then pressurized to 60 psi with hydrogen and
shaken for 24 hours. The reaction mixture was filtered through
Celite and the filter cake washed with 50 mL dichloromethane. The
solvents were then evaporated to yield the final polymer
(quantitative yield). Complete deprotection was determined by the
absence of the benzyl protecting group peaks in the .sup.1H NMR
spectrum at 5.06 (s, 2H, PhCH.sub.2), 7.27-7.33 (m, 5H,
aromatic).
Example 13
Poly(benzyloxy glycerol thiol
carbonate-co-.epsilon.-caprolactone)
##STR00078##
[0259] 5-(benzyloxymethyl)-1,3-dithian-2-one and
.epsilon.-capro-thiollactone are combined with varying ratios (to a
total of 10.0 mmol) in a 10 mL schlenk flask and subsequently
evacuated and flushed with N.sub.2 three times. Meanwhile, the
catalyst (Sn(oct).sub.2, 6.5 .mu.L, 0.02 mmol, monomer/initiator
ratio=500) is evacuated in a small flask for 60 minutes. The
Schlenk flask is partially submerged in a thermostatted oil bath,
preheated to 140.degree. C. Toluene (400 .mu.L) is added to the
catalyst and the mixture injected via syringe to the monomers. The
reaction is stirred for 48 hours, removed from heat, and cooled to
room temperature. The polymer is dissolved in dichloromethane (10
mL) and precipitated in cold methanol. The solvent is decanted and
subsequently dried by evaporation. The resulting polymer forms
either a viscous oil or white solid precipitate depending on the
carbonate content of the copolymer.
Example 14
Poly(hydroxy glycerol thiol
carbonate-co-.epsilon.-caprolactone)
##STR00079##
[0261] Poly(benzyloxy glycerol thiol
carbonate-co-.epsilon.-caprolactone) is dissolved in 50 mL dry
dichloromethane inside a Parr bottle. 10% Pd/C (50 mg) and 20%
Pd(OH).sub.2/C (50 mg) are added to the solution. The reaction
mixture is evacuated and purged with hydrogen three times. The
flask is pressurized to 60 psi with hydrogen and shaken for 24
hours. The reaction mixture is filtered through Celite and the
filter cake washed with 50 mL of dichloromethane. The solvents are
evaporated to yield the final polymer.
Example 15
Poly(stearic acid thiol carbonate-co-.epsilon.-caprolactone)
##STR00080##
[0263] Poly(benzyloxy glycerol thiol
carbonate-co-.epsilon.-caprolactone), stearic acid, and DMAP are
dissolved in 100 mL dry dichloromethane. DCC is added to the
reaction mixture and a white precipitate forms. The mixture is
stirred for 24 hours at room temperature under nitrogen. The
precipitate compound is isolated by filtration and the filtrate was
concentrated. The concentrated filtrate is dissolved in
dichloromethane and precipitated in cold methanol (25 mL). The
solvent is decanted and subsequently dried by evaporation.
Example 16
Fabrication of Paclitaxel Containing PLGA Microparticles
[0264] Bioabsorbable poly D,L-lactide-co-glycolide (PLGA)
microparticles can be used for the delivery of paclitaxel. The
fabrication techniques used to create PLGA microparticles were
modified from Edlund & Albertsson and Wang et. al. (Edlund et
al., Adv. Polymer Sci., 157:67-112, 2001; Wang et al., Chem. Pharm.
Bull., (Tokyo) 44:1935, 1996) and utilized a water in oil emulsion
technique. First, 0.5 g of 75:25 PLGA (Absorbable Polymer
International, Birmingham, Ala.) tablets (the greater the ratio of
lactic acid to glycolic acid the slower the release) were dissolved
in 4 mL dichloromethane (Sigma Aldrich, St. Louis, Mo.) using a
vortexing device. After the plastic was completely dissolved, 50 mg
of paclitaxel (Taxol, MP Biomedical Irvine, Calif.) previously
solubilized in .about.100 .mu.l of dimethyl sulfoxide (DMSO, Fisher
Hampton, N.H.), was added and further vortexed. In the fabrication
of control PLGA beads only DMSO was added. The solution was placed
in 10 ml of 5% polyvinyl alcohol surfactant (Fisher) and vortexed
for 15 minutes (or sonicated using a probe tip sonicator) and
stirred overnight. The microparticles were collected and washed
three times in 50 mL of distilled/deionized water. Following
washing, the microparticles were lyophilized (freeze dried) and
stored at -20.degree. C. to insure the stability of Paclitaxel. The
encapsulation efficiency of taxol by the microparticles was
determined to be 74%+/-4% by HPLC analysis.
Example 17
Synthesis of Nanoparticles by Miniemulsion
[0265] Nanoparticles were prepared using a modification of a
miniemulsion polymerization method previously reported (Landfester
et al., Macromolecules 32:5222-8, 1999). Briefly,
5-methyl-2-(2,4,6-trimethoxyphenyl)-[1,3]-5-diox-anylmethyl
methacrylate and 2,2'-azobis(2-methylpropionitrile) (AIBN), a
free-radical initiator, were dissolved in dichloromethane, followed
by removal of the solvent via rotary evaporation until a viscous
mixture remained. Alternatively,
5-methyl-2-(2,4,6-trimethoxyphenyl)-[1,3]-5-diox-anylmethyl
methacrylate, 0.25 mg of paclitaxel, and
2,2'-azobis(2-methylpropionitrile) (AIBN), a free-radical
initiator, were dissolved in dichloromethane, followed by removal
of the solvent via rotary evaporation until a viscous mixture
remained. This viscous mixture was then mixed with a solution of
sodium dodecyl sulfate, a stabilizing surfactant, in 10 mM pH 8
phosphate buffer. This mixture was then sonicated for 1 hour (1
second pulses with a 2 second delay) with 30 W of power, forming
the miniemulsion and allowing the solvent to evaporate. Following
sonication, the miniemulsion was transferred onto a
temperature-controlled oil bath and stirred at 65.degree. C. for 2
hours to initiate the free-radical polymerization. The resulting
polymeric nanoparticles were then dialyzed against 5 mM pH 8
phosphate buffer over two days to remove excess surfactant and
salts.
Example 18
Synthesis of Nanoparticles Using Photoinitiation
[0266]
5-Methyl-2-(2,4,6-trimethoxyphenyl)-[1,3]-5-dioxan-5-yl-methyl
methacrylate was dissolved in dichloromethane, followed by removal
of the solvent via rotary evaporation until a viscous mixture
remained. Alternatively, methyl-2-phenyl-[1,3]-5-dioxanylmethyl
methacrylate and 0.25 mg of paclitaxel was dissolved in
dichloromethane, followed by removal of the solvent via rotary
evaporation until a viscous mixture remained. This viscous oil was
then mixed with a solution of sodium dodecyl sulfate, the
stabilizing surfactant, in 20 mM triethanolamine buffer. This
mixture was then sonicated for 30 min (1 s pulses with a 2 s delay)
with 30 W of power, forming the miniemulsion and allowing the
solvent to partially evaporate. Following sonication, Eosin Y and
1-vinyl-2-pyrrolidone were added to the emulsion to give final
concentrations of 0.2 mM and 2 mM, respectively. This mixture was
then exposed to light from a mercury arc lamp operating at 300 W
for 10 min while being stirred vigorously, causing polymerization.
Following photopolymerization, the particles were stirred overnight
while open to the air to allow any remaining solvent to evaporate.
The resulting polymeric nanoparticles were then dialyzed against 5
mM pH 8 phosphate buffer over two days to remove excess surfactant
and salts.
Example 19
Nanoparticles Prepared by a Precipitation Method
[0267] 5-Methyl-2-(2,4,6-trimethoxyphenyl)-[1,3]-5-dioxanylmethyl
methacrylate (0.45 g, 1.2 mmol) and benzoyl peroxide (2.6 mg, 0.011
mmol) were dissolved in dry toluene (10 mL). The flask was
evacuated and refilled with nitrogen three times to remove oxygen.
The mixture was then stirred at 70.degree. C. for 14 hours. The
solvent was removed by rotary evaporation, and the remaining
material was dissolved in CH.sub.2Cl.sub.2 (5 mL) and precipitated
in cold diethyl ether (50 mL). The solid precipitate was collected
by vacuum filtration. The product was obtained as a white powder at
36.5% yield.
[0268] Nanoparticles were prepared by first dissolving the polymer
(50 mg) in CH.sub.2Cl.sub.2 (1.0 mL) and dissolving sodium dodecyl
sulfate (50 mg) in deionized water (10 mL). Alternatively,
nanoparticles were prepared by first dissolving the polymer (50 mg)
and paclitaxel (0.5 mg) in CH.sub.2Cl.sub.2 (1.0 mL) and dissolving
sodium dodecyl sulfate (50 mg) in deionized water (10 mL). The
organic solution was then added to the aqueous surfactant solution,
and this mixture was sonicated at 30 W of power for 5 minutes to
produce the emulsion. The mixture was stirred while open to the
atmosphere overnight to evaporate the excess CH.sub.2Cl.sub.2.
Dialysis using a membrane with a 3400 molecular weight cutoff was
used to remove excess surfactant. Nanoparticles prepared using this
monomer do not swell at pH>1.
Example 20
Fabrication of Poly(hydroxy glycerol
carbonate-co-.epsilon.-caprolactone) Drug-Eluting
Microparticles
[0269] Poly(hydroxy glycerol carbonate-co-.epsilon.-caprolactone)
microparticles were used for the delivery of pemetrexed. The
fabrication techniques used to create the microparticles utilize a
water in oil in water emulsion technique. First, 0.5 g of 20:80
poly(hydroxy glycerol carbonate-co-.epsilon.-caprolactone) was
dissolved in 4 mL dichloromethane (Sigma Aldrich, St. Louis, Mo.)
using a vortexing device. After the polymer was completely
dissolved, 50 mg of pemetrexed previously solubilized in 0.9% NaCl,
was added and further vortexed. In the fabrication of control
poly(hydroxy glycerol carbonate-co-.epsilon.-caprolactone) beads
only 0.9% NaCl was added. The solution was placed in 10 ml of 5%
poly vinyl alcohol surfactant (Fisher) and vortexed for 15 minutes
(or sonicated using a probe tip sonicator) and stirred overnight.
The microparticles were collected and washed three times in 50 ml
of distilled/deionized water. Following washing, the microparticles
were lyophilized (freeze dried) and stored at -20.degree. C. to
insure the stability of pemetrexed.
Example 21
Fabrication of Poly(hydroxy glycerol
carbonate-co-.epsilon.-caprolactone) Nanoparticles with Fluorescent
Tag
[0270] 7-(diethylamino)coumarin-3-carboxylic acid (0.005 g, 19.5
nmol), poly(5-hydroxy-1,3-dioxan-2-one-co-.epsilon.-caprolactone)
(1.5 g, 2.6 mmol, 22 mol % carbonate), DCC (0.129 g, 0.63 mmol),
and DMAP (0.032 g, 0.26 mmol) were dissolved in DCM (20 mL). The
solution was stirred at RT for 18 hours. The DCU was filtered and
the solvent evaporated (quantitative yield). The crude product was
redissolved in THF, purified using Sephadex LH-20 chromatography
and further dialyzed (Pierce, 3,500 MWCO) for approximately 48
hours to ensure all residual unbound dye was removed.
[0271] Coumarin-bound copolymer particles were prepared by an
emulsion/solvent evaporation method. Briefly, 1.0 g of copolymer
was dissolved in 20 mL dichloromethane. The solution was poured
into a mixture of 200 mL deionized water containing 0.5% w/v SDS.
The emulsion was stirred for 5 minutes before being sonicated
(.about.30 W) for 30 minutes, and finally dialyzed for
approximately 48 hours to remove the SDS.
[0272] The nanoparticle stock solution (5 mg/mL) was diluted to a
final concentration of 0.01 mg/mL with serum-free medium
(Dulbecco's Modified Eagle Medium). A549 human lung carcinoma cells
(American Type Culture Collection, Manassas, Va.) were plated onto
a 96 well plate at a density of 5,000 cells/well and incubated
overnight, or until about 90% confluence. The medium from each well
was removed and replaced with 100 .mu.L of 0.01 mg/mL nanoparticle
solution and the cells were subsequently incubated with the
particles for 2 hours. The nanoparticle suspension was then
removed, the cells were washed directly three times with PBS, and
the cells were imaged immediately via fluorescence microscopy with
a FITC filter.
Example 22
Fabrication of Poly(stearic acid
carbonate-co-.epsilon.-caprolactone) Nanoparticles
[0273] The nanoparticles were prepared by an emulsion/solvent
evaporation method. Briefly, poly(stearic acid
carbonate-co-.epsilon.-caprolactone) was dissolved in 20 mL
dichloromethane. Alternatively, poly(stearic acid
carbonate-co-.epsilon.-caprolactone) was dissolved in 20 mL
dichloromethane containing either 1 or 10 wt % paclitaxel per
weight of polymer. The solution was poured into a mixture of 200 mL
deionized water containing 0.5% w/v SDS. The emulsion was stirred
for 5 minutes before being sonicated (.about.30 W) for 30 minutes,
and finally dialyzed for approximately 1 hour to remove the
SDS.
Example 23
Nanoparticle Expanding in Acidic but not Neutral Conditions
##STR00081##
[0275] A sample of the nanoparticles from Example 18 was diluted in
buffer at a pH 4, 5, or 7.4 and maintained at 37.degree. C. The
diameter of the particles was then measured at regular time
intervals using dynamic light scattering (DLS), showing how the
particles increased in size over time. Prior to each DLS
measurement, the samples were sonicated for 5 seconds to break up
aggregates. Particle swelling from 100 nm in diameter to near 1
.mu.m in diameter was observed (see FIG. 9). In addition, the
release of free 2,4,6-trimethoxybenzaldehyde was observed using
UV/Vis spectroscopy at a wavelength of 292 nm, also indicating
deprotection of the polymer side groups (see FIG. 10).
[0276] These particles are useful for controlled release
applications as well as for cosmetic applications in which the
increase in volume could reduce wrinkles of increase the sized of
tissue into which these polymers are injected.
Example 24
Nanoparticle and Swelling from a Sugar Analog
##STR00082##
[0278] Synthesis of
1,2:5,6-di-O-isopropylidene-3-O-methacryloyl-.alpha.-D-glucofuranose:
The synthesis of this compound was carried out as described by
Black et al. and is described briefly. (Black et al., Journal of
the Chemical Society, 4433-4439, 1963).
1,2:5,6-di-O-isopropylidene-.alpha.-D-glucofuranose (1.00 g, 3.86
mmol) and methacrylic anhydride (1.2 mL, 1.2 g, 8.1 mmol) were
dissolved in pyridine (5 mL) and stirred at 65.degree. C. for 3.5
hours. Then water (2.5 mL) was added, and stirring at 65.degree. C.
was continued for another 1.5 hours and then at room temperature
overnight. The mixture was extracted with hexanes (5 mL.times.3),
and the combined hexanes extracts were then washed with 1M NaOH (15
mL.times.3) and deionized water (15 mL), followed by drying over
Na.sub.2SO.sub.4. The solvent was removed using rotary evaporation,
and the remaining compound was dried under high vacuum. The product
was obtained as a clear oil at 74.2% yield.
[0279] Nanoparticles were prepared from the resulting product by
methods described herein. A sample of the nanoparticles was diluted
in 0.1M HCl and maintained at 25.degree. C. The diameter of the
particles was then measured at regular time intervals using dynamic
light scattering (DLS), showing how the particles increased in size
over time (FIG. 12). FIG. 12 shows that at a pH of about 1.0, the
particle size changes from about 200 nm to about 1600 nm over the
course of about 24 hours, whereas at a pH of about 3.0, the
particle size is stable over the same time period.
Example 25
Formation of Single-Layer Polymer Films
[0280] Polymer films were cast onto glass by depositing a polymer
solution comprised of an individual copolymer including but not
limited to poly(stearic acid carbonate-co-.epsilon.-caprolactone),
dissolved in dichloromethane, tetrahydrofuran, or toluene, using a
microsyringe. The solvent was removed by slow evaporation overnight
and then placed under reduced pressure for 24 hours.
Example 26
Formation of Multi-Layered Polymer Films
[0281] Poly(stearic acid carbonate-co-.epsilon.-caprolactone) films
were adhered between poly(lactic-co-glycolic acid) films A
poly(lactic-co-glycolic acid)/dichloromethane solution was
deposited onto glass using a microsyringe to form a film. A
poly(stearic acid
carbonate-co-.epsilon.-caprolactone)/dichloromethane solution was
deposited onto the poly(lactic-co-glycolic acid) film using a
microsyringe to form a second layer. A poly(lactic-co-glycolic
acid)/dichloromethane solution was deposited onto the poly
poly(stearic acid carbonate-co-.epsilon.-caprolactone) film using a
microsyringe to form a third layer.
Example 27
Deposition of Polymer Films on a Substrate
[0282] Polymer films were cast onto substrates composed of either
glass, collagen, pericardium, TEFLON.RTM., or titanium by
depositing a polymer solution comprised of an individual copolymer
including but not limited to poly(stearic acid
carbonate-co-.epsilon.-caprolactone), dissolved in dichloromethane,
tetrahydrofuran, or toluene, using a microsyringe. The solvent was
removed by slow evaporation overnight and then placed under reduced
pressure for 24 hours.
Example 28
Incorporation 10-hydroxycaptothecin into Polymer Films
[0283] Drug loaded polymeric films were cast or sprayed onto glass
by depositing a polymer solution of poly(stearic acid
carbonate-co-.epsilon.-caprolactone), dichloromethane, and
10-hydroxycamptothecin, using a microsyringe or aerosol device. The
solvent was removed by slow evaporation overnight and then placed
under reduced pressure for 24 hours.
Example 29
Incorporation and Patterning of 10-Hydroxycaptothecin into Polymer
Films
[0284] Patterned drug loaded polymeric films were cast onto glass
by using a microprinter or microsyringe by depositing a polymer
solution of poly(stearic acid carbonate-co-.epsilon.-caprolactone),
dichloromethane, and 10-hydroxycamptothecin, in a controlled manner
to form patterns such as stripes and dots. The solvent was removed
by slow evaporation overnight and then placed under reduced
pressure for 24 hours. This method can also be used with more than
one polymer simultaneously.
Example 30
Release of 10-Hydroxycamptothecin from
Poly(.epsilon.-caprolactone)
[0285] Drug-loaded polymer films were cast onto glass by depositing
a polymer solution comprised of poly(caprolactone) (5 mg),
dichloromethane (50 .mu.L), and 10-hydroxycamptothecin (100 .mu.g),
using a microsyringe. The solvent was removed by slow evaporation
over night and then placed under reduced pressure for 24 hours. An
initial burst was seen over the first two days, releasing at a rate
of about 5 .mu.g/day.
[0286] Drug-loaded polymer films were also cast onto glass by
depositing a polymer solution comprised of poly(stearic
carbonate-co-.epsilon.-caprolactone) (5 mg), dichloromethane (50
.mu.L), and paclitaxel (100 .mu.g), using a microsyringe. The
solvent was removed by slow evaporation over night and then placed
under reduced pressure for 24 hours. The resulting films were
homogenous and opaque, with good adherence to the glass substrate.
The films released taxol over time.
Example 31
Release of 10-Hydroxycamptothecin or Paclitaxel from Poly(stearic
acid carbonate-co-.epsilon.-caprolactone)
[0287] Drug-loaded polymer films were cast onto glass by depositing
a polymer solution comprised of poly(stearic acid
carbonate-co-.epsilon.-caprolactone) (5 mg), dichloromethane (50
.mu.L), and 10-hydroxycamptothecin (100 .mu.g), using a
microsyringe. The solvent was removed by slow evaporation over
night and then placed under reduced pressure for 24 hours. A slight
initial burst was seen over the first two days, releasing at a rate
of about 3 .mu.g/day. Continuous release occurred over at least 30
days at a nearly constant rate of about 1 .mu.g/day.
[0288] Alternatively, drug-loaded polymer films were cast onto
glass by depositing a polymer solution comprised of poly(stearic
carbonate-co-.epsilon.-caprolactone) (5 mg), dichloromethane (50
.mu.L), and paclitaxel (100 .mu.g), using a microsyringe. The
solvent was removed by slow evaporation over night and then placed
under reduced pressure for 24 hours. The resulting films were
homogenous and opaque, with good adherence to the glass substrate.
The films released taxol over time.
Example 32
Release of 10-Hydroxycamptothecin from Poly(hydroxy glycerol
carbonate-co-.epsilon.-caprolactone)
[0289] Drug-loaded polymer films were cast onto glass by depositing
a polymer solution comprised of poly(hydroxy glycerol
carbonate-co-.epsilon.-caprolactone) (5 mg), dichloromethane (50
.mu.L), and 10-hydroxycamptothecin (100 .mu.g), using a
microsyringe. The solvent was removed by slow evaporation over
night and then placed under reduced pressure for 24 hours. An
initial burst was seen over the first day, releasing at a rate of
about 18 .mu.g/day. Continuous release occurred over at least 30
days, beginning at a rate of 3 .mu.g/day and slowly decreasing to
less than 1 .mu.g/day at four weeks.
Example 33
In Vitro Tumor Cytoxicity with Paclitaxel-Loaded Poly(stearic acid
carbonate-co-.epsilon.-caprolactone) Nanoparticles
[0290] Lewis Lung Carcinoma (LLC) cells were washed with sterile
phosphate buffered saline (PBS) and trypsinized. The cells were
then counted using a Coulter counter and plated 3,000 cells/well in
96 well plates. Cells were serum starved overnight and then treated
with empty nanoparticles, paclitaxel-loaded nanoparticles (10%
paclitaxel), and paclitaxel-loaded nanoparticles (1% paclitaxel)
for a five day period. A positive control contained 10% FBS or the
same concentration of FBS provided for treated cells, while a
negative control lacked FBS. At the completion of the assay the
cells were incubated with 50 .mu.L of 1.times. Thiazolyl Blue
Tetrazolium Bromide (MTT, Sigma) dissolved in PBS at 37.degree. C.
for two hours. The media was then aspirated and 100 .mu.L of DMSO
was added to each well. The plates were then placed on a shaking
device for 10 minutes and the wells turned purple, corresponding
with the numbers of viable mitochondria in the well. The plates
were placed on an ELISA reader and scanned at a wavelength of 570
nm. The absorbance values were normalized to values from a known
number of stained cells. No cytotoxicity was observed with the
empty nanoparticles (as a control, FIG. 3), whereas cytotoxicity
was observed with the taxol loaded nanoparticles, as shown in FIGS.
4 and 5.
Example 34
Release of 10-Hydroxycamptothecin from Poly((lauric, myristic,
palmitic, or stearic) glycerol
carbonate-co-.epsilon.-caprolactone)
[0291] Drug-loaded polymer films were cast onto glass by depositing
a polymer solution comprised of poly((lauric, myristic, palmitic,
or stearic) carbonate-co-.epsilon.-caprolactone) (5 mg),
dichloromethane (50 .mu.L), and 10-hydroxycamptothecin (100 .mu.g),
using a microsyringe. The solvent was removed by slow evaporation
over night and then placed under reduced pressure for 24 hours. An
initial burst was seen over the first day, releasing at a rate of
about 8-10 .mu.g/day. Continuous release occurred over at least 49
days, beginning at a rate of 1-3 .mu.g/day and slowly decreasing to
less than 1 .mu.g/day at four weeks (see FIG. 6). FIG. 6 shows that
increasing the hydrophobicity of the polymer decreases release from
the polymers. Intermediate release profiles to those shown can be
obtained by mixing or blending the polymers.
Example 35
Release of 10-Hydroxycamptothecin from Poly(stearic glycerol
carbonate-co-.epsilon.-caprolactone) on Pericardium Strips
[0292] Drug-loaded polymer films were cast onto pericardium by
depositing a polymer solution comprised of poly(stearic acid
carbonate-co-.epsilon.-caprolactone) (5 mg), dichloromethane (50
.mu.L), and 10-hydroxycamptothecin (100 .mu.g), using a
microsyringe. The solvent was removed by slow evaporation overnight
and then placed under reduced pressure for 24 hours. An initial
burst was seen over the first day, releasing at a rate of about 10
.mu.g/day. Continuous release occurred over at least 40 days,
beginning at a rate of 3 .mu.g/day and slowly decreasing to less
than 1 .mu.g/day at four weeks (see FIG. 7).
Example 36
Cell Culture and Cell Proliferation Assays
[0293] Melanoma B 16 (murine), Calu 6 (human lung carcinoma), A549
(human lung carcinoma), and LLC (murine Lewis Lung Carcinoma) were
incubated (37.degree. C., 5% CO.sub.2) with MEM (with 10% fetal
bovine serum (FBS) and 1% essential amino acids. The media was
change once every three days. When not cultured, all cell lines
were stored in RPMI freezing media at -80.degree. C. (with 50% FBS,
40% RPMI and 10% dimethyl sulfoxide (DMSO)). Cell lines were
trypsinized from 15 cm plates and seeded into 96 well plates at a
concentration of 3000 cells per well. All cell lines were cultured
for a period of at least three days before being tested in cell
proliferation assays.
[0294] Tumor cells were washed with sterile phosphate buffered
saline (PBS) and trypsinized. The cells were then counted using a
Coulter counter and plated 3,000 cells/well in 96 well plates.
Cells were serum starved overnight and then treated with
paclitaxel, control microparticles, or paclitaxel loaded
microparticles the next day. A positive control contained 10% FBS
or the same concentration of FBS provided for treated cells, while
a negative control lacked FBS. At the completion of the assay the
cells were incubated with 50 .mu.l of 1.times. Thiazolyl Blue
Tetrazolium Bromide (MTT, Sigma) dissolved in PBS at 37.degree. C.
for two hours. The media was then aspirated and 100 .mu.l of DMSO
was added to each well. The plates were then placed on a shaking
device for 10 minutes and the wells turned purple, corresponding
with the numbers of viable mitochondria in the well. The plates
were placed on an ELISA reader and scanned at a wavelength of 570
nm. The absorbance values were normalized to values from a known
number of stained cells. The dose of paclitaxel at which 50% of
cells are killed, or LD50, was determined to be between 1-10 ng/mL.
Approximately 125,000 paclitaxel loaded microparticles/mL were
necessary to achieve similar paclitaxel concentrations and cell
death.
Example 37
Anti-Tumor Response In Vitro
[0295] Cell proliferation assays testing the effects of paclitaxel
were performed using three tumor cell lines. Lewis Lung Carcinoma
(LLC), Melanoma and Calu6 (human lung cancer) cell lines were
plated at 3,000 cells/well and when established, cultured in media
with/without paclitaxel. Some cultures were maintained with optimal
growth factors (serum) whereas others were serum starved
(non-growing) cultures. At the end of 5 days, tumor cell
proliferation was assessed via MTT analysis. Data was plotted by
normalization to the positive and negative control cultures as 0%
and 100% inhibition, respectively. The results indicated that media
containing paclitaxel at a concentration of 1-10 ng/mL reliably
inhibits growth of the LLC, melanoma, and Calu6 tumor cell lines in
proliferation assays. This data was obtained using media containing
10% FBS (positive control).
[0296] Cell proliferation assays were utilized to study the effects
of paclitaxel-loaded microparticles on tumor growth. Tumor cells
were plated at 3000 cells/well and positive (serum-rich) and
negative (serum-poor) cultures were used to signify 0% and 100%
growth inhibition respectively. It was found that the addition of
100,000-500,000 microparticles/ml results in inhibition equal to
paclitaxel concentrations of .about.10 ng/mL despite the presence
of serum rich media Inhibition of tumor growth was not present with
control (DMSO) microparticles that do not contain paclitaxel. These
results demonstrate that paclitaxel-loaded microparticles are an
effective means of drug delivery and specifically result in an
effective anti-tumor response in vitro.
[0297] To determine the kinetics of the anti-tumor response
elicited by paclitaxel-loaded microparticles and to assess for a
potential "burst effect" of drug release, a cell proliferation
assay comparing paclitaxel-loaded microparticles and DMSO (control)
microparticles using the melanoma cell line was run for five
consecutive days with a plate undergoing MTT analysis each day for
days 2-5. Paclitaxel loaded microparticles and DMSO microparticles
were added to serum rich media and individually assessed on tumor
cells of the same plate. The results demonstrate a dose-dependent
inhibition with the administration of paclitaxel microparticles,
but little difference in inhibition for a given dose on day 2 vs.
day 5. These findings confirm that paclitaxel microparticles
inhibit tumor growth quickly with little difference in growth
inhibition following the initial exposure. This is consistent with
an immediate release of drug and maximum burst effect.
Example 38
Nanoparticle Uptake by Cells
[0298] Fluorescent nanoparticles were created as describe herein
with the addition of 2 mol % of a fluorescent co-monomer. Non-small
cell lung cancer A549 cells were seeded onto a 96-well plate
(20,000 cells/well) and incubated overnight at 37.degree. C. and 5%
carbon dioxide. The media was then removed from the wells and
replaced with a buffered saline solution containing fluorescent
nanoparticles at a concentration of 0.5, 1, or 5 mg/mL. Controls
not containing nanoparticles were also performed. After incubation
at 37.degree. C. and 5% carbon dioxide for 0.5, 1, 2, or 4 hours,
the particle suspension was removed, and the cells were washed
twice with buffered saline and then lysed with 100 .mu.L of 0.5%
Triton X-100.RTM. in 0.2 M sodium hydroxide. Measuring the
fluorescence of the cell lysate samples (excitation wavelength=470
nm, emission wavelength=518 nm) and comparing to a standard curve
gave the concentration of nanoparticles in the samples. The cells
showed increasing uptake over time and with decreased nanoparticle
concentration in the buffer.
Example 39
Cell Culture
[0299] Mesothelioma cell line (MSTO-211H) is incubated (37.degree.
C., 5% CO.sub.2) with MEM (with 10% fetal bovine serum (FBS), 1%
essential amino acids, and 1% Penicillin/Streptomyocin with L
glutamine (Pen/Strep), F-12 HAM (with 10% FBS and 1% Pen/Strep) and
DMEM (with 10% FBS and 1% Pen/Strep) media respectively, with media
changes once every three days. When not cultured, all cell lines
were stored in RPMI freezing media at -80.degree. C. (with 50% FBS,
40% RPMI and 10% dimethyl sulfoxide (DMSO)). Cell lines were
trypsinized from 15 cm plates and seeded into 96 well plates at a
concentration of 3000 cells per well. All cell lines were cultured
for a period of at least three days before being tested in cell
proliferation assays.
Example 40
Pemetrexed In Vitro Mesothelioma Tumor Cell Proliferation
Assays
[0300] Cells were washed with sterile phosphate buffered saline
(PBS) and trypsinized. The cells were then counted using a Coulter
counter and plated 3,000 cells/well in 96 well plates. Cells were
serum starved overnight and then treated with pemetrexed, control
poly(hydroxy glycerol carbonate-co-.epsilon.-caprolactone)
microparticles or pemetrexed loaded poly(hydroxy glycerol
carbonate-co-.epsilon.-caprolactone) microparticles the next day. A
positive control contained 10% FBS or the same concentration of FBS
provided for treated cells, while a negative control lacked FBS. At
the completion of the assay the cells were incubated with 50 .mu.l
of 1.times. Thiazolyl Blue Tetrazolium Bromide (MTT, Sigma)
dissolved in PBS at 37.degree. C. for two hours. The media was then
aspirated and 100 .mu.l of DMSO was added to each well. The plates
were then placed on a shaking device for 10 minutes and the wells
turned purple, corresponding to the number of viable mitochondria
in the well. The plates were placed on an ELISA reader and scanned
at a wavelength of 570 nm. The absorbance values were normalized to
values from a known number of stained cells. The dose of pemetrexed
at which 50% of cells were killed, or LD50, was determined to be
between 0.1-1.0 .mu.g/mL Approximately 250,000-500,000 pemetrexed
loaded microparticles/well or .about.100 microparticles/tumor cell
were necessary to achieve similar pemetrexed concentrations and
cell death.
Example 41
Release of 10-Hydroxycamptothecin from Films for In Vitro Tumor
Cell Proliferation Assays
[0301] Polymer films containing 10-hydroxycamptothecin (10-HCPT)
were cast onto glass by depositing a polymer solution comprised of
poly(stearic acid carbonate-co-.epsilon.-caprolactone) (5 mg),
dichloromethane (50 .mu.L) and 10-hydroxycamptothecin (100 .mu.g)
using a microsyringe. Films were exposed to Ultraviolet (UV)
radiation overnight prior to being placed into 12-well plates
containing 3,000 Lewis Lung Carcinoma (LLC) cells per well. Cell
cultures were incubated with films for multiday exposure (FIG. 1)
or 24-hour (FIG. 2) periods and then assayed for viability using
MTT staining protocols. Both exposure durations provided effective
inhibition of tumor cell proliferation out to 25 days and the
multidayexposure period continued to effectively kill tumor cells
as late as Day 30. By comparison, exposure to films containing no
drug (unloaded films) under the same exposure conditions generated
no cytotoxic effects (see FIGS. 1 and 2). These results indicate
that our polymer films containing 10-hydroxycamptothecin (10-HCPT)
can effectively kill tumor cells for as long as thirty days.
Example 42
In Vitro Tumor Cytoxicity with Paclitaxel-Loaded Nanoparticles
[0302] Cultured tumor cell lines for lung (murine LLC and human
A549 and NCI-H460), melanoma (B16), mesothelioma (human MSTO-211H),
breast (human MCF7), human esophageal sarcoma (LMS05) cancers were
cultured at 37.degree. C./5% CO.sub.2 in the appropriate media
supplemented with 10% Fetal Bovine Serum (FBS) and 1%
penicillin/streptomycin with L-glutamine, with the exception of MEM
media which also contained 1% essential amino acids and 1 mg/mL of
bovine insulin. Each cell line was seeded at concentrations of
3,000 (LLC, B16, A549, MSTO-211H, NCI-H460), 5,000 (MCF7) or 10,000
(LMSO5) cells/well into 96-well assay plates in order to establish
the appropriate tumor cell plating density. Cells were co-cultured
for 7 days with paclitaxel-loaded and unloaded
5-methyl-2-(2,4,6-trimethoxyphenyl)-1,3-dioxan-5-yl-methyl
methacrylate nanoparticles (fabrication described above). After the
incubation period, cells were assayed for viability via MTT
analysis and plotted as the percentage of viable cells using a
positive control (culture containing no nanoparticles) to represent
100% viability.
[0303] FIG. 16 shows the results for LLC and FIG. 17 shows the
results for MSTO-211H experiments and indicate that
paclitaxel-loaded, but not unloaded, nanoparticles reduce cell
proliferation for several different cancer lines at a
concentrations as low as 10 .mu.g/mL of polymer nanoparticles
(containing approximately 100 ng/mL of Paclitaxel, consistent with
the IC.sub.50 of free paclitaxel). FIG. 18 shows the anti-cancer
activity of paclitaxel loaded nanoparticle with LLC cells in vitro.
These results indicate that our polymers have sustained release,
and that when loaded with an anti-cancer agent can actively kill
cancer cells for sustained periods of time, which we believe may
inhibit recurrence of the cancer.
Example 43
Quantification of Microparticle Adherence to Lung
[0304] To investigate microparticle attachment to lung tissue, PLGA
microparticles were suspended in Pluronic NF-127 or water and each
solution was painted onto the intact mouse lungs. The lungs were
rocked side-to-side in PBS, simulating the coating of pleural
fluid, for differing time periods and the percent of adherent
microparticles was determined using a coulter counter. After a one
hour exposure to PBS wetting the lung, the supernatant was removed
and counted for adherent microparticles. Plates were thoroughly
rinsed to avoid counting adhesion to the plate rather then lung.
The percent of microparticles adhering to lung was found by
averaging the number of microparticles released to the supernatant.
It was found that there is a much higher percent attachment
(89.9+/-10) of microparticles loaded in Pluronic NF127 gel than
with microparticles loaded in a water control (28.3+/-28). The
difference in these attachment percentages is statistically
significant (P<0.05), and indicates that adhesives such as
PLURONIC.RTM. NF127 gel can be used to adhere microparticles to
tissue, such as lung tissue.
Example 44
Anti-Tumor Response In Vivo
[0305] Lewis Lung Carcinoma cells (LLC) (750,000) were injected
with or without 50 million PLGA-Paclitaxel loaded microparticles
subcutaneously in C57BL6 mice. It is well established that this
tumor dose results in subcutaneous tumor nodules within 1 week with
rapid growth requiring sacrifice within 2-3 weeks. In the time
following injection it was found that tumor size was significantly
decreased in animals receiving LLC cells and PLGA-paclitaxel
microparticles vs. LLC cells alone. At sacrifice, untreated tumors
weighed 3.8.+-.0.9 grams whereas tumors co-injected with
PLGA-paclitaxel loaded microparticles (n=7) weighed 1.0.+-.1.4
grams (Day 13-17, p<0.05). The majority of PLGA-paclitaxel
loaded microparticle treated animals developed minimal evidence of
tumor implantation or growth. No toxicity from PLGA-paclitaxel
administration was noted. Thus, the data suggests that locally
delivered chemotherapy via microparticles can deter the growth and
establishment of lung carcinoma in vivo in this subcutaneous model
of tumor implantation.
[0306] Fabricated microparticles were 1-5 .mu.m in diameter,
smooth, and lack porosity suggesting that they will maintain a
relatively constant drug release for a long period of time. It is
estimated that paclitaxel has tumorcidal effects in the 5-10 ng
range, which is estimated to be about 3 microparticles per cell. In
vivo co-injection of tumor cells and Paclitaxel loaded
microparticles demonstrate that a dose of 100 million
microparticles completely inhibits growth and establishment of
tumor cells. Proliferation assays and in vivo injections have also
demonstrated that the control PLGA microparticles are inert and
without effect on tumor growth.
Example 45
Anti-Tumor Response of Functional Loaded Nanoparticles In Vivo
[0307] The anti-tumor effects of chemotherapy-loaded nanoparticles
from Example 18 were evaluated in well-established subcutaneous
tumor models. Mouse LLC or human MSTO-211H cancer cell lines were
implanted into C57BL6 or nude mice, respectively. Cultured tumor
cell suspensions were co-injected with drug-loaded nanoparticles
into the subcutaneous tissues of the back of mice. Both "high" (25
microgram paclitaxel) and "low" (2.5 microgram paclitaxel) doses of
nanoparticles were evaluated. Animals injected with tumor cells
alone in PBS, tumor with identical doses of unloaded functional or
loaded non-functional (non-expansile) nanoparticles served as
controls. Tumor size was monitored biweekly and animals were
euthanized if tumors reached 2 cm in size. As demonstrated FIG. 13,
both the high and low doses of paclitaxel-loaded functional
nanoparticles inhibited tumor growth in mice (p<<0.0001), and
were much more effective than even the paclitaxel-loaded but
non-expansile nanoparticles. These data clearly demonstrate that
the anti-tumor effects of paclitaxel-loaded functional
nanoparticles seen in vitro translates to suppression of tumor
growth in vivo.
Example 46
Anti-Tumor Response of Subcutaneous Polymer Film Implantation In
Vivo
[0308] The anti-tumor effects of chemotherapy-loaded polymer film
implants were also evaluated using a subcutaneous tumor model.
After induction of anesthesia, C57BL/6 mice were shaved and skin on
the back of the mouse was prepped in a sterile fashion. An incision
of 0.8 cm was made between the shoulders of the mice. The
connective tissue under the skin was dissected with a pair of
sterilized tweezers to make a subcutaneous pocket. A piece of
sterilized polymer film dried on a pericardium strip (0.8.times.0.8
cm) was inserted into the subcutaneous pocket with the drug-loaded
side of the film placed upward towards the skin, and the incision
was closed with 5-0 sutures. Mice were monitored until fully
recovered from anesthesia, given analgesics and were housed in a
SPF (specific pathogen free) grade animal facility. Two days were
allowed for healing of the incision, before 750,000 mouse LLC tumor
cells were injected subcutaneously on top of the implanted film via
a 27-gauge needle.
[0309] Tumor size was monitored biweekly and animals were
euthanized if tumors reached 2 cm in size. Tumor growth did not
occur overtop of polymer films loaded with 30 .mu.g
10-hydroxycamptothecin (10-HCPT) in any of the experimental mice
(see FIG. 14). This is in contrast to the significant tumor growth
that occurred directly on the unloaded polymer films in over 75% of
the animals tested. Some animals that had received 10-HCPT loaded
polymer films did develop tumors with delayed follow-up but these
tumors were always in the periphery of the pocket and away from the
film itself (see FIG. 15). In addition to the delay in tumor
appearance, these tumors were significantly smaller in size
(p<0.005), confirming that the 10-HCPT loaded films prevented
and/or delayed local tumor growth in the in vivo tumor model.
Example 47
No Delay in Wound Healing in the Presence of Subcutaneous
Chemotherapy-Loaded Polymer Films
[0310] Polymer films were subcutaneously implanted on the back of
C57BL/6 mice under anesthesia as described herein. Healing was
assessed by inspection in animals that received 10-HCPT loaded
polymer films, unloaded polymer films or sham surgery where
subcutaneous pockets were prepared but no film was implanted. All
incisions were closed with 5-0 suture. There was no evidence of
wound dehiscence early or late (up to 21 days) in animals that
received loaded or unloaded films. In addition, there was no
difference in erythema or wound appearance among animals with films
versus sham surgery.
Example 48
Local Drug Release of Subcutaneous Polymer Film Implantation In
Vivo
[0311] The local drug release pattern of subcutaneously implanted
drug-loaded polymer films in vivo was examined. Polymer films were
subcutaneously implanted on the back of C57BL/6 mice under
anesthesia as described above. At weekly intervals following
implantation of the films, the surrounding tissues were harvested.
These tissues were cut in a radial fashion away from the film and
sequentially segmented at 1 mm distances away from the film, thus
providing tissue for assessment at various distances and directions
away from the drug-loaded film The concentration of the drug eluted
at the various distances was then ascertained within each tissue
segment using HPLC for the specific drug of interest. The gradient
of drug concentration within a 2 cm diameter of the center of the
film was then plotted to establish the drug release kinetics and
drug distribution into the surrounding tissues in vivo.
Example 49
Tumor Recurrence Model of Subcutaneous Tumor Resection
[0312] The suppression of tumor recurrence by drug-loaded
nanoparticles and drug-loaded polymer films are also being examined
using a well established in vivo tumor model (Qadri et al., Ann
Thorac Surg 80:1046-51, 2005). Similar to the subcutaneous tumor
model utilized in Example 48, 750,000 LLC tumor cells were injected
subcutaneously and allowed to grow. The tumor was subsequently
resected through a 1.0 cm incision parallel to the tumor and the
entire tumor is removed and the incision closed in control animals.
Unloaded or drug-loaded nanoparticles or polymer films are applied
onto the tumor bed of experimental animals and the skin incision is
similarly closed. Animals are assessed biweekly for evidence of
recurrent tumor growth which our pilot studies have demonstrated
occurs aggressively in control animals that do not receive
drug-loaded nanoparticles or polymer films.
Example 50
In Vivo Intraperitoneal Mesothelioma Animal Experiment with
Paclitaxel-Loaded Nanoparticles
[0313] The ability of drug-loaded nanoparticles to inhibit the
growth of human tumor cells in vivo within the intraperitoneal
cavity has also been investigated using a murine model of
mesothelioma using a well established in vivo tumor model
(Adusumilli et al., J Thorac Cardiovasc Surg. 132:1179-88, 2006).
Cultured mesothelioma tumor cells (5 million MSTO-211H) were
co-injected with paclitaxel-loaded functional nanoparticles via an
i.p. injection into the lower abdomen of NU/J (nude) mice. Animals
injected with tumor cells alone in PBS or tumor with identical
doses of loaded non-functional (non-expansile) nanoparticles served
as controls for tumorigenicity and nanoparticle toxicity,
respectively.
Example 51
SEM of Films
[0314] Drug-loaded polymer films were cast onto glass by depositing
a polymer solution comprised of poly(stearic
carbonate-co-.epsilon.-caprolactone) (5 mg), dichloromethane (50
.mu.L), and 10-hydroxycamptothecin (100 .mu.g), using a
microsyringe. The solvent was removed by slow evaporation over
night and then placed under reduced pressure for 24 hours. Prior to
imaging, the films were coated with 7 nm of Au/Pd. The films were
imaged using scanning electron microscopy. The surfaces of the
films appeared smooth and non-porous with fibrous-like
microtexture. As shown in FIG. 8, cross-section images also
revealed a smooth, non-porous interior with consistent thicknesses
throughout the length of the film of approximately 40 microns.
Example 52
SEM of Nanoparticles
[0315] Samples for scanning electron microscope (SEM) imaging were
prepared by diluting a sample of nanoparticles to a concentration
of 0.25 mg/mL with deionized water. A 10 .mu.L portion of the
diluted sample was then placed on a clean aluminum stub and allowed
to air dry. Prior to imaging, the samples were coated with a 5 nm
layer of Au/Pt. Samples were then imaged on a Zeiss SUPRA 40VP
field emission SEM using an accelerating voltage of 1 kV. The image
in FIG. 11 shows particles from about 1 to 50 microns with most of
the particles between 5 and 20 microns.
Example 53
Contact Angle Measurements
[0316] Polymer films were cast onto glass substrates and the
contact angle of each film was determined using contact angle
goniometry. Contact angles ranged from 75-120.degree.. For example,
the contact angle of poly(stearic acid
carbonate-co-.epsilon.-caprolactone) was 118.degree.. The contact
angle of glass is about 35.degree..
Example 54
Thermal Transition Measurements
[0317] Thermal transitions of each polymer were measured using
differential scanning calorimetry. Polymers composed of
.epsilon.-caprolactone and benzyloxy glycerol carbonate monomers
were formed with the following carbonate mole fractions: 0.05,
0.10, 0.20, 0.30, 0.40, 0.50, 1.00. Glass transition temperatures
ranged from -64.degree. C. to -10.degree. C. and melting
temperatures ranged from 22.degree. C.-57.degree. C. Some
copolymers were semi-crystalline and other copolymers were
amorphous.
Other Embodiments
[0318] It is to be understood that while the invention has been
described in conjunction with the detailed description thereof, the
foregoing description is intended to illustrate and not limit the
scope of the invention, which is defined by the scope of the
appended claims. Other aspects, advantages, and modifications are
within the scope of the following claims.
* * * * *